<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">RSX</journal-id>
<journal-id journal-id-type="hwp">sprsx</journal-id>
<journal-id journal-id-type="nlm-ta">Reprod Sci</journal-id>
<journal-title>Reproductive Sciences</journal-title>
<issn pub-type="ppub">1933-7191</issn>
<issn pub-type="epub">1933-7205</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1933719112446080</article-id>
<article-id pub-id-type="publisher-id">10.1177_1933719112446080</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>2-Methoxyestradiol in the Pathophysiology of Endometriosis: Focus on Angiogenesis and Therapeutic Potential</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Machado-Linde</surname>
<given-names>Francisco</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-1933719112446080">1</xref>
<xref ref-type="corresp" rid="corresp1-1933719112446080"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pelegrin</surname>
<given-names>Pablo</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff2-1933719112446080">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sanchez-Ferrer</surname>
<given-names>Maria L.</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-1933719112446080">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Leon</surname>
<given-names>Josefa</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff3-1933719112446080">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cascales</surname>
<given-names>Pedro</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff4-1933719112446080">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Parrilla</surname>
<given-names>Juan J.</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-1933719112446080">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1933719112446080">
<label>1</label>Department of Gynecology and Obstetrics, Hospital Virgen Arrixaca, Murcia, Spain</aff>
<aff id="aff2-1933719112446080">
<label>2</label>Inflammation and Experimental Surgery Group, Centro de Investigación Biomédica en Red en el Área temática de Enfermedades Hepáticas y Digestivas (CIBERehd), Hospital Virgen Arrixaca, Murcia, Spain</aff>
<aff id="aff3-1933719112446080">
<label>3</label>Department of Hospital Pharmacy, Hospital Morales Meseguer, Murcia, Spain</aff>
<aff id="aff4-1933719112446080">
<label>4</label>Department of General Surgery, Hospital Virgen Arrixaca, Murcia, Spain</aff>
<author-notes>
<corresp id="corresp1-1933719112446080">Francisco Machado-Linde, Department of Gynecology and Obstetrics, Hospital Virgen Arrixaca, 30120 Murcia, Spain Email: <email>fmachadol@hotmail.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>10</month>
<year>2012</year>
</pub-date>
<volume>19</volume>
<issue>10</issue>
<fpage>1018</fpage>
<lpage>1029</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">Society for Gynecologic Investigation</copyright-holder>
</permissions>
<abstract>
<p>Endometriosis is a common condition among women of childbearing potential in which ectopic endometrial tissue is found outside the uterine cavity. Neoangiogenesis plays a major role in the development of endometriotic implants. Some evidence suggests that a disorder in the balance of proangiogenic and antiangiogenic factors that favors the former is induced by local hypoxia and is mediated by the hypoxia-inducible factor-vascular endothelium growth factor pathway could partially explain the development of this condition in some women. 2-methoxyestradiol is a biologically active metabolite of estradiol having antiangiogenic action. Changes in estradiol homeostasis have been locally observed in endometriosis. In this review, we summarize current knowledge of endometriosis pathophysiology, in particular, the balance between local 2-methoxyestradiol production and angiogenesis, which could promote the development of endometriotic lesions. 2-Methoxyestradiol emerges as a promising new candidate for the treatment of endometriosis.</p>
</abstract>
<kwd-group>
<kwd>2-methoxyoestradiol</kwd>
<kwd>estrogen</kwd>
<kwd>angiogenesis</kwd>
<kwd>apoptosis</kwd>
<kwd>endometriosis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1933719112446080">
<title>Introduction</title>
<p>Endometriosis is a common gynecological disorder defined by the presence of tissue similar to the endometrium (glands and endometrial stroma) outside the endometrial cavity, most commonly in the ovaries and peritoneum. Endometriosis is an estrogen-dependent disease and, therefore, affects women of reproductive age almost exclusively. The most common symptoms are chronic pelvic pain, dysmenorrhea, dyspareunia, and infertility. In some cases, the symptoms are so disabling that they noticeably impair the patient’s quality of life.<sup>
<xref ref-type="bibr" rid="bibr1-1933719112446080">1</xref>
</sup> The prevalence of the disease in the general population is between 10% and 15% but increases to 30% to 50% in women with clinical signs of pelvic pain or infertility.<sup>
<xref ref-type="bibr" rid="bibr2-1933719112446080">2</xref>
</sup> The main pathologic conditions associated with the disease are inflammation, peritoneal fibrosis, and formation of ovarian cysts and adhesions. Endometriosis has also been related to an increased risk of ovarian cancer, particularly of clear and endometrioid cells.<sup>
<xref ref-type="bibr" rid="bibr3-1933719112446080">3</xref>
</sup>
</p>
</sec>
<sec id="section2-1933719112446080">
<title>Pathogenesis of Endometriosis</title>
<p>The pathogenesis of endometriosis has not yet been elucidated, probably because it is a complex multifactorial disease (<xref ref-type="fig" rid="fig1-1933719112446080">Figure 1</xref>). There are several hypotheses that could complement each other. It was originally assumed that a local endogenous or an exogenous stimulus caused metaplasia of the peritoneal mesothelial cells and that metaplastic lesions grow once a blood supply is established after local invasion of the peritoneum.<sup>
<xref ref-type="bibr" rid="bibr4-1933719112446080">4</xref>
</sup> In 1924, Halban<sup>
<xref ref-type="bibr" rid="bibr5-1933719112446080">5</xref>
</sup> suggested that endometrial cells could spread systemically through the vascular or lymph system. This theory could explain the presence of distant endometriotic lesions, such as in lung, brain, eyes, or skin. Endometriosis also has a polygenic-inherited component, and its incidence is 6 to 9 times higher in first-degree relatives of patients with endometriosis than in unaffected individuals.<sup>
<xref ref-type="bibr" rid="bibr6-1933719112446080">6</xref>
</sup> A strong familial tendency has also been reported in nonhuman primates.<sup>
<xref ref-type="bibr" rid="bibr7-1933719112446080">7</xref>
</sup> The most commonly accepted hypothesis was established by Sampson<sup>
<xref ref-type="bibr" rid="bibr8-1933719112446080">8</xref>
</sup> in 1927 and introduces the term retrograde menstruation. In this hypothesis, viable endometrial cells reach the abdominal cavity through the fallopian tubes during menstruation. Women susceptible to the disease probably have an optimal peritoneal environment for the adhesion of endometrial cells to the peritoneal wall (<xref ref-type="fig" rid="fig1-1933719112446080">Figure 1</xref>). Endometrial cells can then enzymatically degrade the extracellular matrix and invade the mesothelial cell layer, underlying basal membrane, and stroma. Endometriotic lesions lead to a new blood supply by recruiting and creating blood vessels from neighboring vasculature,<sup>
<xref ref-type="bibr" rid="bibr9-1933719112446080">9</xref>
</sup> a process known as angiogenesis. However, the invasion of endometriotic lesions has only been observed in animal models and not in humans.<sup>
<xref ref-type="bibr" rid="bibr10-1933719112446080">10</xref>
</sup> A drawback for the retrograde menstruation hypothesis is that the process occurs in more than 90% of women,<sup>
<xref ref-type="bibr" rid="bibr11-1933719112446080">11</xref>
</sup> hence other conditions that allow endometrial tissue growth must coexist. In this regard, a determining factor could be the individual’s genetically established angiogenic potential, as a wide genetic variation in the angiogenic potential has been demonstrated in mice<sup>
<xref ref-type="bibr" rid="bibr12-1933719112446080">12</xref>
</sup> (<xref ref-type="fig" rid="fig1-1933719112446080">Figure 1</xref>).</p>
<fig id="fig1-1933719112446080" position="float">
<label>Figure 1.</label>
<caption>
<p>Pathophysiology and molecular mechanisms involved in endometriosis. Endometrial cells may establish and grow in a local optimal environment condition to generate endometriosis. This local environment is dictated by (<italic>i</italic>) neoangiogenesis, (<italic>ii</italic>) proinflammatory factors, and (<italic>iii</italic>) an imbalance of estrogens in favor of high estradiol and low 2-methoxyestradiol (2-ME2) levels. Genetic factors favoring endometriosis could be affecting any of the 3 processes that dictate the local environment.</p>
</caption>
<graphic xlink:href="10.1177_1933719112446080-fig1.tif"/>
</fig>
</sec>
<sec id="section3-1933719112446080">
<title>Neoangiogenesis and Endometriosis</title>
<p>Angiogenesis is the process whereby new vessels develop from existing ones. Physiologic angiogenesis is essential for embryogenesis but rarely occurs in adults, except for reproductive tissue and wound healing.<sup>
<xref ref-type="bibr" rid="bibr13-1933719112446080">13</xref>
</sup> In women, nonpathologic severe angiogenesis occurs in the ovary during the formation of the corpus luteum and in the endometrium during the menstrual cycle.<sup>
<xref ref-type="bibr" rid="bibr14-1933719112446080">14</xref>
</sup> Therefore, vascular tissue is usually in a quiescence state, maintained by a balance between angiogenesis inhibitors and activators.<sup>
<xref ref-type="bibr" rid="bibr15-1933719112446080">15</xref>
</sup> The rupture of this balance, in favor of excessive angiogenesis, has been described in conditions such as rheumatoid arthritis, diabetic retinopathy, psoriasis, cancer, and endometriosis.<sup>
<xref ref-type="bibr" rid="bibr15-1933719112446080">15</xref>,<xref ref-type="bibr" rid="bibr16-1933719112446080">16</xref>
</sup> Since Folkman<sup>
<xref ref-type="bibr" rid="bibr17-1933719112446080">17</xref>
</sup> first studied neoangiogenesis as a necessary factor for tumor growth, it has been recognized that angiogenesis plays a major role in the establishment and growth of other conditions such as endometriotic lesions.<sup>
<xref ref-type="bibr" rid="bibr18-1933719112446080">18</xref>
</sup> Although the underlying mechanism for neoangiogenesis in endometriosis is not well known, several studies have confirmed neovascularization in and around endometriotic lesions<sup>
<xref ref-type="bibr" rid="bibr19-1933719112446080">19</xref>
</sup> and a significant correlation between a diagnosis of endometriosis and the angiogenic activity of the peritoneal fluid.<sup>
<xref ref-type="bibr" rid="bibr20-1933719112446080">20</xref>
</sup> Therefore, it is well accepted that a blood supply is essential for the survival of endometriotic implants and the development of endometriosis, as blood is crucial for providing nutrients and growth factors and for promoting recruitment of inflammatory cells to the endometriotic lesions, as described in a review by Groothuis et al.<sup>
<xref ref-type="bibr" rid="bibr21-1933719112446080">21</xref>
</sup>
</p>
<p>Few studies have investigated the vascularization of peritoneal endometriotic lesions.<sup>
<xref ref-type="bibr" rid="bibr22-1933719112446080">22</xref>,<xref ref-type="bibr" rid="bibr23-1933719112446080">23</xref>
</sup> However, recent findings clearly show that angiogenesis is often associated with the disease and the optimal peritoneal microenvironment for the adhesion of endometrial cells and that factors such as a chronic inflammatory environment and the inherent properties of human endometrium help maintain an angiogenic stimulus and activate vascular remodeling, thus achieving the optimal conditions for endometriotic tissue growth.<sup>
<xref ref-type="bibr" rid="bibr24-1933719112446080">24</xref>
</sup> In the peritoneal fluid of patients with endometriosis there is an alteration between proangiogenic and antiangiogenic growth factors.<sup>
<xref ref-type="bibr" rid="bibr25-1933719112446080">25</xref>
</sup> In addition, there is an increase in activated inflammatory macrophages, which produce proangiogenic factors.<sup>
<xref ref-type="bibr" rid="bibr26-1933719112446080">26</xref>
<xref ref-type="bibr" rid="bibr27-1933719112446080"/>–<xref ref-type="bibr" rid="bibr28-1933719112446080">28</xref>
</sup> However, despite the identification of many angiogenic factors, the detailed underlying mechanism of endometriotic lesion revascularization is still unclear. Among the proangiogenic proteins synthesized by the endometrium, vascular endothelium growth factor (VEGF) is the most potent and effective regulator of endothelial cell mitogenesis.<sup>
<xref ref-type="bibr" rid="bibr29-1933719112446080">29</xref>
</sup> The VEGF was originally identified as a vascular permeability factor, due to its effect in increasing blood vessel permeability, but bears its name because of its mitogenic and survival effects it has on endothelial cells.<sup>
<xref ref-type="bibr" rid="bibr30-1933719112446080">30</xref>
</sup> The factor is mainly found in the epithelium of endometriotic implants, particularly in red implants and endometriomas. High concentrations of soluble VEGF have been found in the pelvic fluid of patients with endometriosis.<sup>
<xref ref-type="bibr" rid="bibr31-1933719112446080">31</xref>
</sup> The regulation of VEGF is controlled at transcription and posttranscription levels, and VEGF messenger RNA transcription is induced by different agents, hypoxia being one of the most potent factors inducing VEGF expression via the hypoxia-inducible factor (HIF)-1α.<sup>
<xref ref-type="bibr" rid="bibr32-1933719112446080">32</xref>
</sup> The HIF-1 is a heterodimer made up of 2 subunits, α and β. The HIF-1α subunit is strongly regulated by oxygen levels, whereas HIF-1β is constitutively expressed in the cells. The HIF-1α is promptly degraded under normal oxygen conditions but stabilized under hypoxia conditions, and its expression can be stimulated by growth factors and gene disorders. The HIF-1 is a transcription factor that interacts with hypoxia-response elements to stimulate the transcription of over 60 genes, including multiple proangiogenic genes, such as VEGF, genes involved in drug resistance, and genes controlling cell proliferation, survival, and invasion.<sup>
<xref ref-type="bibr" rid="bibr33-1933719112446080">33</xref>
</sup>
</p>
<p>Some authors have postulated that endometriotic lesions can acquire new vessels by enhancing activation of the HIF-VEGF pathway induced by hypoxia.<sup>
<xref ref-type="bibr" rid="bibr34-1933719112446080">34</xref>,<xref ref-type="bibr" rid="bibr35-1933719112446080">35</xref>
</sup> Increased VEGF expression by estrogens has been found in human endometrial cells in vitro, in human and rat breast cancer cell lines in vitro and in vivo, and in experimental animal models of rat uterus and primate endometrium.<sup>
<xref ref-type="bibr" rid="bibr36-1933719112446080">36</xref>
<xref ref-type="bibr" rid="bibr37-1933719112446080"/>–<xref ref-type="bibr" rid="bibr38-1933719112446080">38</xref>
</sup> These studies support the role of ovarian steroids in the development of endometriotic implants.<sup>
<xref ref-type="bibr" rid="bibr39-1933719112446080">39</xref>
</sup> It is also widely reported that endometriosis is an estrogen-dependent disease, since endometrial cells require continuous stimulation with estrogens to grow and there is a local increase in estrogen production in endometrial lesions, as reported in a review by Rizner.<sup>
<xref ref-type="bibr" rid="bibr40-1933719112446080">40</xref>
</sup> Several studies suggest that estrogens can directly affect angiogenesis and vascular development and, in fact, estrogens induce endothelial cell proliferation and VEGF expression, which increase the levels of calcium-dependent nitric oxide synthase and angiogenesis in vivo through several pathways.<sup>
<xref ref-type="bibr" rid="bibr31-1933719112446080">31</xref>,<xref ref-type="bibr" rid="bibr41-1933719112446080">41</xref>
</sup>
</p>
<p>A proinflammatory environment favors angiogenesis, similar to the wound healing process. Interestingly, endometriosis has characteristics of both the wound healing process and chronic inflammatory disease. Endometriotic tissue shows high levels of macrophages, T cells, and mast cells, and a low granulocyte count. There is evidence of extracellular matrix remodeling, fibromuscular differentiation, and cyclooxygenase (COX)-2 synthesis.<sup>
<xref ref-type="bibr" rid="bibr21-1933719112446080">21</xref>,<xref ref-type="bibr" rid="bibr42-1933719112446080">42</xref>
</sup> Expression of COX-2 is strongly favored by the inflammatory environment, but local high estrogen levels can also upregulate its expression. Cyclooxygenase 2 leads to the production of different lipid mediators derived from arachidonic acid (prostanoids), including prostaglandin E2, which in turn becomes a potent inducer of aromatase expression.<sup>
<xref ref-type="bibr" rid="bibr42-1933719112446080">42</xref>
</sup> This positive local feedback circuit increases the production of estradiol (E<sub>2</sub>) and COX-2 levels in endometriotic tissue.<sup>
<xref ref-type="bibr" rid="bibr43-1933719112446080">43</xref>
</sup> Cyclooxygenase 2 is also a potent factor during angiogenesis,<sup>
<xref ref-type="bibr" rid="bibr44-1933719112446080">44</xref>
</sup> and local production of both estrogens and COX-2 contributes to creating a proangiogenic environment (<xref ref-type="fig" rid="fig1-1933719112446080">Figure 1</xref>).</p>
<p>Proinflammatory macrophages and endometrial cells in the peritoneum of women with endometriosis also promote angiogenesis due to elevated oxidative stress, which increase VEGF secretion.<sup>
<xref ref-type="bibr" rid="bibr45-1933719112446080">45</xref>
</sup> It has recently been reported that endoplasmic reticulum stress, a new type of oxidative stress, could be relevant in conditions such as endometriosis, since it mainly occurs in specialized epithelial cells with a dynamic secretory function, such as endometrial cells.<sup>
<xref ref-type="bibr" rid="bibr46-1933719112446080">46</xref>
</sup>
</p>
</sec>
<sec id="section4-1933719112446080">
<title>Estrogens and Endometriosis</title>
<p>As already described in a previous section, there is a strong correlation between high levels of estrogens and endometriosis. Endometriosis mainly affects women of childbearing potential but is occasionally diagnosed in postmenopausal women, usually those with relatively high estrogen levels or who are receiving hormone replacement therapy.<sup>
<xref ref-type="bibr" rid="bibr47-1933719112446080">47</xref>
</sup> Estrogen suppression with gonadotropin-releasing factor (GnRh) agonists can provide some regression of endometrial lesions.<sup>
<xref ref-type="bibr" rid="bibr48-1933719112446080">48</xref>
</sup> However, estrogen recovery occurs after GnRh discontinuation and, in many cases, during therapy. Furthermore, there is a high relapse rate of endometriosis after conservative surgery, in contrast with an absence or large decrease in the endometriosis relapse rate after bilateral oophorectomy compared to no adnexectomy.<sup>
<xref ref-type="bibr" rid="bibr49-1933719112446080">49</xref>
</sup> This clinical evidence suggests that endometriosis grows and regresses in an estrogen-dependent manner. Lastly, several cases of endometriosis lesions have been reported in elderly men who received high doses of estrogens for prostate cancer treatment, in whom the lesions appeared in the bladder and paratesticular region.<sup>
<xref ref-type="bibr" rid="bibr50-1933719112446080">50</xref>,<xref ref-type="bibr" rid="bibr51-1933719112446080">51</xref>
</sup>
</p>
<p>Higher levels of E<sub>2</sub> have been described in the menstrual blood of women with endometriosis compared to that of healthy women, suggesting that E<sub>2</sub> is locally formed in the endometrium of patients with endometriosis<sup>
<xref ref-type="bibr" rid="bibr52-1933719112446080">52</xref>
</sup> (<xref ref-type="fig" rid="fig1-1933719112446080">Figure 1</xref>). This is further confirmed by the aberrant expression of several enzymes of estrogen metabolism in the ectopic endometrium, which has high levels of aromatase and suppression of type 2 17, β-hydroxysteroid dehydrogenase.<sup>
<xref ref-type="bibr" rid="bibr53-1933719112446080">53</xref>
<xref ref-type="bibr" rid="bibr54-1933719112446080"/>–<xref ref-type="bibr" rid="bibr55-1933719112446080">55</xref>
</sup> In turn, this can lead to high E<sub>2</sub> biosynthesis and low E<sub>2</sub> degradation, excess local E<sub>2</sub>, and decreased levels of protective progesterone,<sup>
<xref ref-type="bibr" rid="bibr55-1933719112446080">55</xref>
</sup> which results in further proliferation of ectopic endometrium as reported by Rizner.<sup>
<xref ref-type="bibr" rid="bibr40-1933719112446080">40</xref>
</sup>
</p>
</sec>
<sec id="section5-1933719112446080">
<title>2-Methoxyestradiol</title>
<p>Estradiol metabolism results in the formation of several metabolites with different degrees of estrogen activity; one of these metabolites is (17β)-2-methoxyestra-1,3,5(10)-triene-3,17-diol, or 2-methoxyestradiol (2-ME2), which is formed from cytochrome (CY) P450-dependent conversion of E<sub>2</sub> to 2-hydroxyestradiol and then methylated by catechol-<italic>O</italic>-methyl transferase (COMT). Many tissues can actively produce 2-ME2, since COMT is a ubiquitous enzyme found in different tissues and organs, such as the liver, kidney, intestine, stomach, spleen, brain, pancreas, or lung.<sup>
<xref ref-type="bibr" rid="bibr56-1933719112446080">56</xref>
</sup> Plasma concentrations of 2-ME2 range from a low picomolar concentration in postmenopausal women to nanomolar concentrations during pregnancy. Concentrations in the micromolar range are only found in tissues with high local E<sub>2</sub> concentrations, such as the breast or ovary.<sup>
<xref ref-type="bibr" rid="bibr57-1933719112446080">57</xref>
</sup> 2-Methoxyestradiol is mainly metabolized to the inactive substance 2-methoxyestrone via hydroxylation and dehydrogenation, but some studies have reported that 2-ME2 could also be demethylated into other estrogen metabolites.<sup>
<xref ref-type="bibr" rid="bibr58-1933719112446080">58</xref>
</sup> 2-Methoxyestradiol has a very short half-life in rodents and a poor bioavailability in humans, probably due to conjugation in position 3 or 17 with glucuronic sulfate or acid.<sup>
<xref ref-type="bibr" rid="bibr59-1933719112446080">59</xref>,<xref ref-type="bibr" rid="bibr60-1933719112446080">60</xref>
</sup> There are several 2-ME2 artificial analogues that have been developed to improve the efficacy and pharmacokinetics of this compound.<sup>
<xref ref-type="bibr" rid="bibr61-1933719112446080">61</xref>
</sup>
</p>
</sec>
<sec id="section6-1933719112446080">
<title>Antiproliferative Action of 2-ME22</title>
<p>In the early 1980s, 2-ME2 was found to act as an antiproliferative compound in cell lines, and recently this action has been widely demonstrated in a high variety of endothelial tumors and malignant cell lines<sup>
<xref ref-type="bibr" rid="bibr62-1933719112446080">62</xref>
<xref ref-type="bibr" rid="bibr63-1933719112446080"/>
<xref ref-type="bibr" rid="bibr64-1933719112446080"/>–<xref ref-type="bibr" rid="bibr65-1933719112446080">65</xref>
</sup> (<xref ref-type="fig" rid="fig2-1933719112446080">Figure 2</xref>). The first biological activity reported for 2-ME2 was that it caused mitotic accumulation and formation of abnormal mitotic spindles.<sup>
<xref ref-type="bibr" rid="bibr66-1933719112446080">66</xref>
</sup> The antiproliferative and anticytotoxic activity of 2-ME2 is not shared by E<sub>2</sub>, which suggests that these actions are E<sub>2</sub>-receptor independent.<sup>
<xref ref-type="bibr" rid="bibr67-1933719112446080">67</xref>
</sup> In most cell types, treatment with 2-ME2 results in an arrest of the cell cycle in the Go/G1 phase as a result of the inhibition of DNA synthesis. However, in other cell types there is an arrest of the cell cycle in the G2/M phase, probably because of the actions of 2-ME2 on the microtubule cytoskeleton.<sup>
<xref ref-type="bibr" rid="bibr68-1933719112446080">68</xref>
</sup> In human and rat vascular smooth muscle cells (VSMC) from aorta, 2-ME2 has been shown to arrest cell growth via double blockade of the cell cycle.<sup>
<xref ref-type="bibr" rid="bibr69-1933719112446080">69</xref>
</sup> The antiproliferative action of 2-ME2 has also been attributed to its blocking action on extracellular matrix production, collagen synthesis, and tubulin polymerization.<sup>
<xref ref-type="bibr" rid="bibr70-1933719112446080">70</xref>
<xref ref-type="bibr" rid="bibr71-1933719112446080"/>–<xref ref-type="bibr" rid="bibr72-1933719112446080">72</xref>
</sup> These actions are directly involved in the pathophysiology of several vascular disorders, such as atherosclerosis and asthma.<sup>
<xref ref-type="bibr" rid="bibr73-1933719112446080">73</xref>,<xref ref-type="bibr" rid="bibr74-1933719112446080">74</xref>
</sup>
</p>
<fig id="fig2-1933719112446080" position="float">
<label>Figure 2.</label>
<caption>
<p>Physiologic events induced by 2-methoxyestradiol. The 2-ME2 could be beneficial for the treatment of endometriosis because it induces apoptosis, is anti-inflammatory, and blocks cell proliferation and angiogenesis. However, as a side effect in the treatment of endometriosis, 2-ME2 displays low estrogen activity which could lead to cell proliferation.</p>
</caption>
<graphic xlink:href="10.1177_1933719112446080-fig2.tif"/>
</fig>
<p>The mechanism whereby 2-ME2 induces these actions is unknown, but could be due to its antioxidant properties. Reactive oxygen species (ROS) are natural by-products of aerobic metabolism and their production correlates with normal cell proliferation through activation of growth-related signaling pathways. Indeed, exposure to low levels of ROS can increase the growth of many types of mammalian cells, whereas scavengers of ROS suppress normal cell proliferation in human and rodent fibroblasts.<sup>
<xref ref-type="bibr" rid="bibr75-1933719112446080">75</xref>
</sup> In this regard, it is well established that free radicals oxidize membrane lipids and integral membrane proteins and that such oxidations can alter signal-transduction mechanisms controlling cell migration and proliferation, processes critical to vascular neointimal formation. 2-Methoxyestradiol is a potent antioxidant and protects phospholipids residing in the plasma membrane of VSMC from free radical-induced peroxidation and peroxidation-induced cell growth and migration.<sup>
<xref ref-type="bibr" rid="bibr76-1933719112446080">76</xref>,<xref ref-type="bibr" rid="bibr77-1933719112446080">77</xref>
</sup> Other mechanisms through which 2-ME2 may have antiproliferative action are increases in the levels of cell proliferation inhibitory compounds (such as nitric oxide, cyclic adenosine monophosphate, or prostacyclin) or reductions the levels of components that stimulate cell proliferation (such as endothelin 1 or catecholamine).<sup>
<xref ref-type="bibr" rid="bibr78-1933719112446080">78</xref>
</sup>
</p>
</sec>
<sec id="section7-1933719112446080">
<title>Apoptotic Actions of 2-ME2</title>
<p>2-Methoxyestradiol is an agent that induces apoptosis in several cell lines in vitro and in animal models in vivo by different mechanisms (<xref ref-type="fig" rid="fig2-1933719112446080">Figure 2</xref>). The apoptotic activity of 2-ME2 is restricted for cells with active proliferation, such as activated tumor or endothelial cells. 2-Methoxyestradiol does not induce apoptosis in normal mammary epithelial cells or quiescent endothelial cells.<sup>
<xref ref-type="bibr" rid="bibr68-1933719112446080">68</xref>
</sup> However, in VSMC the data provided are contradictory: there is evidence for 2-ME2-induced apoptosis, whereas other authors report data that do not support these findings,<sup>
<xref ref-type="bibr" rid="bibr69-1933719112446080">69</xref>,<xref ref-type="bibr" rid="bibr79-1933719112446080">79</xref>
</sup> and such discrepancies could be due to different experimental conditions possibly affecting the proliferation status of VSMC. Furthermore, not all tumors are sensitive to 2-ME2-induced cell death, even though the antitumor activity of 2-ME2 has been widely demonstrated in multiple in vivo models.<sup>
<xref ref-type="bibr" rid="bibr80-1933719112446080">80</xref>
</sup>
<bold> </bold>To date, the cellular events triggered by 2-ME2 are still not fully understood.</p>
<p>The mechanism of 2-ME2-induced apoptosis appears to vary considerably in the different cells examined, and there is evidence for the involvement of the extrinsic and intrinsic apoptotic pathways. This mechanism confers a broad-spectrum activity for 2-ME2 (<xref ref-type="fig" rid="fig2-1933719112446080">Figure 2</xref>). The extrinsic pathway of apoptosis is induced by the activation of death receptors in the cell surface,<sup>
<xref ref-type="bibr" rid="bibr81-1933719112446080">81</xref>
</sup> and in different tumor and endothelial cells, 2-ME2 increases the expression of the death receptor 5, a member of the tumor necrosis factor death receptor family.<sup>
<xref ref-type="bibr" rid="bibr82-1933719112446080">82</xref>
</sup> 2-Methoxyestradiol can also activate the intrinsic apoptotic pathway or mitochondrial apoptosis in different cell types, including endothelial and tumor cells,<sup>
<xref ref-type="bibr" rid="bibr83-1933719112446080">83</xref>
</sup> and correlates with the antiproliferative and cytotoxic effects of 2-ME2 in these cells. In addition, the apoptotic process is regulated by many intracellular-signaling pathways, including the c-Jun NH<sub>2</sub>-terminal kinase (JNK) pathway.<sup>
<xref ref-type="bibr" rid="bibr84-1933719112446080">84</xref>
</sup> In several tumor cell lines (myeloma, colorectal, prostate, breast, and liver) 2-ME2 treatment results in fast activation of JNK and stress-activated protein kinase, with upregulation of Fas, triggering apoptosis.<sup>
<xref ref-type="bibr" rid="bibr85-1933719112446080">85</xref>
</sup> In general, JNK is activated in response to different stress stimuli and induces cellular apoptosis but JNK inhibition dramatically reduces the ability of 2-ME2 to induce apoptosis in myeloma cells.<sup>
<xref ref-type="bibr" rid="bibr85-1933719112446080">85</xref>
</sup> Therefore, JNK activation appears to be important for the apoptotic effects of 2-ME2.<sup>
<xref ref-type="bibr" rid="bibr86-1933719112446080">86</xref>,<xref ref-type="bibr" rid="bibr87-1933719112446080">87</xref>
</sup> Interestingly, the effects of 2-ME2 are independent of p53 status: 2-ME2 induces cell death in cell lines with p53 mutation, meaning that 2-ME2 is effective on both cell types, p53 dependent and p53 independent.<sup>
<xref ref-type="bibr" rid="bibr83-1933719112446080">83</xref>
</sup>
</p>
<p>The role of ROS in the molecular pharmacology of 2-ME2 is an active and contradictory research area. As explained, 2-ME2 appears as antioxidant-chelating ROS and inhibiting proliferation of VSMC.<sup>
<xref ref-type="bibr" rid="bibr76-1933719112446080">76</xref>,<xref ref-type="bibr" rid="bibr77-1933719112446080">77</xref>
</sup> However, other studies have linked 2-ME2 to the stimulation of cellular ROS production, resulting in the release of cytochrome c from the mitochondria and the activation of caspases and apoptosis.<sup>
<xref ref-type="bibr" rid="bibr81-1933719112446080">81</xref>
</sup> Mitochondria are the main producers of ROS in the cell, and the intrinsic pathway of apoptosis and generation of ROS may be closely related.<sup>
<xref ref-type="bibr" rid="bibr75-1933719112446080">75</xref>
</sup> According to the evidence available, the generation of ROS is an important factor mediating apoptosis induced by 2-ME2 in some, but not all, cell types.<sup>
<xref ref-type="bibr" rid="bibr88-1933719112446080">88</xref>
<xref ref-type="bibr" rid="bibr89-1933719112446080"/>
<xref ref-type="bibr" rid="bibr90-1933719112446080"/>–<xref ref-type="bibr" rid="bibr91-1933719112446080">91</xref>
</sup> 2-Methoxyestradiol has also been reported to inhibit superoxide dismutase (SOD) enzymes, which protect cells from damage induced by superoxide radicals, and the inhibition of SOD activity results in the apoptosis of human leukemia cells.<sup>
<xref ref-type="bibr" rid="bibr92-1933719112446080">92</xref>
</sup> Another very important unresolved issue is whether the generation of ROS occurs before early apoptotic events, thus acting as a trigger of apoptosis, or whether it occurs as a result of the activation of the intrinsic or extrinsic apoptotic pathway.<sup>
<xref ref-type="bibr" rid="bibr83-1933719112446080">83</xref>
</sup>
</p>
</sec>
<sec id="section8-1933719112446080">
<title>Antiangiogenic Actions of 2-ME2</title>
<p>2-Methoxyestradiol is a direct inhibitor of angiogenesis due to its antiproliferative and proapoptotic effects in endothelial cells, but it is also an indirect antiangiogenic molecule acting through the inhibition of HIF-1α expression in endothelial and tumor cell<sup>
<xref ref-type="bibr" rid="bibr93-1933719112446080">93</xref>
</sup> (<xref ref-type="fig" rid="fig2-1933719112446080">Figure 2</xref>). As stated earlier, HIF-1 is a proangiogenic transcription factor that stimulates transcription of multiple proangiogenic proteins, including VEGF.<sup>
<xref ref-type="bibr" rid="bibr30-1933719112446080">30</xref>,<xref ref-type="bibr" rid="bibr94-1933719112446080">94</xref>
</sup> 2-Methoxyestradiol reduces VEGF production through HIF-1α inhibition and, therefore, it is tempting to speculate that 2-ME2 might also block the transcription of other proangiogenic genes dependent on HIF-1α.<sup>
<xref ref-type="bibr" rid="bibr94-1933719112446080">94</xref>
</sup> The exact mechanism of HIF-1α inhibition by 2-ME2 is currently unclear, although there is some evidence suggesting that this is due to the disruption of microtubules, similar to the effect of classical microtubule blockers taxol or vincristine.<sup>
<xref ref-type="bibr" rid="bibr93-1933719112446080">93</xref>
</sup> In fact, a recent report suggests that targeting of microtubules is the major molecular mechanism of action of 2-ME2, whereas the other reported targets of 2-ME2 (ie, induction/blocking of cellular ROS, disruption of mitochondrial function and inhibition of HIF) are unlikely to be important contributors to drug action in epithelial cancer cells.<sup>
<xref ref-type="bibr" rid="bibr95-1933719112446080">95</xref>
</sup> Various studies have also shown the importance of HIF-1α in cell proliferation in vitro and in vivo, for example, in colon cancer cells,<sup>
<xref ref-type="bibr" rid="bibr96-1933719112446080">96</xref>
</sup> mouse embryonic stem cells,<sup>
<xref ref-type="bibr" rid="bibr97-1933719112446080">97</xref>
</sup> and immortalized mouse embryonic fibroblasts.<sup>
<xref ref-type="bibr" rid="bibr98-1933719112446080">98</xref>
</sup> Therefore, part of the proapoptotic effects of 2-ME2 could be also mediated by the inhibition of HIF-1α.</p>
<p>The antiantiogenic activity of the natural metabolite 2-ME2 was identified in 1994.<sup>
<xref ref-type="bibr" rid="bibr99-1933719112446080">99</xref>
</sup> 2-Methoxyestradiol inhibits in vitro proliferation, migration, and invasion of endothelial cells and has antiangiogenic effects in several in vivo experimental models. Unlike most antiangiogenic agents, 2-ME2 targets both proliferating endothelial cells and tumor cells, ultimately leading to the initiation of apoptosis.<sup>
<xref ref-type="bibr" rid="bibr83-1933719112446080">83</xref>
</sup> The reduction in tumor vascularization and tumor burden was demonstrated long time ago in preclinical mouse models.<sup>
<xref ref-type="bibr" rid="bibr100-1933719112446080">100</xref>
</sup> The clinical trials using 2-ME2 have demonstrated that this is a well-tolerated, orally active compound that is effective against different tumors, including breast, prostate, and myeloma.<sup>
<xref ref-type="bibr" rid="bibr101-1933719112446080">101</xref>
</sup> 2-Methoxyestradiol inhibits VEGF production by tumor cells; this effect probably contributes to the reduction in tumor neovascularization. However, the antiangiogenic effects of 2-ME2 have also been described in nontumor tissues.<sup>
<xref ref-type="bibr" rid="bibr68-1933719112446080">68</xref>
</sup>
</p>
<p>It can be concluded that the ability of 2-ME2 to act on both the vascular endothelium and the tumor cell is due to its broad-spectrum activity. The inhibition of HIF-1α under normal and hypoxic conditions explains the variety of effects of 2-ME2 and provides a basis for understanding the different effects of 2-ME2 on specific cell types. The effects of 2-ME2-blocked cell migration and invasion could be mediated by HIF-1α inhibition and/or might be a direct result of tubular disruption but correlates with the success of the treatment of highly metastatic cancers with 2-ME2.<sup>
<xref ref-type="bibr" rid="bibr83-1933719112446080">83</xref>,<xref ref-type="bibr" rid="bibr95-1933719112446080">95</xref>
</sup>
</p>
</sec>
<sec id="section9-1933719112446080">
<title>2-Methoxyestradiol and Estrogen Receptors</title>
<p>2-Methoxyestradiol has a low affinity for both types of estrogen receptors (ER-α and -β), consistent with its low estrogen activity (<xref ref-type="fig" rid="fig2-1933719112446080">Figure 2</xref>). There is some evidence that the antiproliferative and proapoptotic actions of 2-ME2 are not ER dependent, but some inconsistent effects have been described. Cell lines lacking ER still sensitive to 2-ME2 and ER antagonists do not attenuate the inhibitory effects of 2-ME2.<sup>
<xref ref-type="bibr" rid="bibr102-1933719112446080">102</xref>
</sup> However, the affinity of 2-ME2 for human ER is about 0.5% of E<sub>2</sub> and due to this low affinity in the breast cancer cell line MCF7<bold> </bold>(which has ER expression), very low concentrations of 2-ME2 caused stimulation of proliferation and growth, while high concentrations induces the expected inhibitory growing actions of 2-ME2.<sup>
<xref ref-type="bibr" rid="bibr64-1933719112446080">64</xref>,<xref ref-type="bibr" rid="bibr103-1933719112446080">103</xref>,<xref ref-type="bibr" rid="bibr104-1933719112446080">104</xref>
</sup> 2-Methoxyestradiol is also able to activate similar gene expression than E<sub>2</sub> in MCF7, and ER antagonists block this effect.<sup>
<xref ref-type="bibr" rid="bibr105-1933719112446080">105</xref>
</sup> Treatment with 2-ME2 induces MCF7 proliferation and formation of tumors in an in vivo mouse model and had no in vivo antitumor effect in the breast cancer cell line MDA-MB-435, which lacks ER expression.<sup>
<xref ref-type="bibr" rid="bibr105-1933719112446080">105</xref>
</sup> Also, extremely high doses of 2-ME2 in rat and dog caused reversible estrogen effects that were not observed at therapeutic doses. These effects are related to the ability of liver microsomes of these species to metabolize 2-ME2 to 2-hydroxyestradiol and 2-hydroxyestrone by CYP450, both metabolites that present estrogen activity<sup>
<xref ref-type="bibr" rid="bibr106-1933719112446080">106</xref>
</sup> (<xref ref-type="fig" rid="fig2-1933719112446080">Figure 2</xref>). These effects are consistent with the hypothesis that the proliferative activity caused by low concentrations of 2-ME2 is a consequence of its metabolization to estrogen metabolites similar to 2-hydroxyestradiol.<sup>
<xref ref-type="bibr" rid="bibr103-1933719112446080">103</xref>
</sup> The ability of the CYP450 enzyme complex to demethylate 2-ME2 to 2-hydroxyestradiol has also been found with the enzymes CYP1A1 and CYP1B1,<sup>
<xref ref-type="bibr" rid="bibr80-1933719112446080">80</xref>
</sup> and this possibility must be considered when designing clinical trials or selecting effective therapeutic combinations. Other studies also suggest that 2-ME2 may have protective effects in the presence of endogenous estrogens. Some authors have reported that 2-ME2 has a dose-dependent inhibitory feedback on CYP1A1 and CYP1B1 enzyme activity. The ability of 2-ME2 to exert these inhibitory effects may be related to the reduction in the metabolism of endogenous estrogens to 2-hydroxyestradiol and 4-hydroxyestradiol to the reactive estrogens semiquinones and quinones. These metabolites, as we know, can generate superoxide free radicals and cause DNA damage. 2-Methoxyestradiol, by inhibiting hepatic and extrahepatic CYP enzymes, can limit the metabolism of E<sub>2</sub> to estrogenically reactive metabolites and, in addition, protect against other procarcinogenic xenobiotics activated by the CYP450-dependent metabolic pathway.<sup>
<xref ref-type="bibr" rid="bibr80-1933719112446080">80</xref>
</sup>
</p>
<p>The potential therapeutic actions of 2-ME2 to induce apoptosis and to inhibit cell proliferation and angiogenesis should be contrasted with the E<sub>2</sub>-like activity of 2-ME2 or its metabolites, which then induce tumor growth, and should be considered when designing and selecting patients for clinical trials<sup>
<xref ref-type="bibr" rid="bibr64-1933719112446080">64</xref>,<xref ref-type="bibr" rid="bibr80-1933719112446080">80</xref>,<xref ref-type="bibr" rid="bibr104-1933719112446080">104</xref>,<xref ref-type="bibr" rid="bibr105-1933719112446080">105</xref>
</sup> (<xref ref-type="fig" rid="fig2-1933719112446080">Figure 2</xref>). In premenopausal women, 2-ME2 may have chemopreventive activity by inhibiting the metabolism of endogenous estrogens and xenobiotics to chemically reactive metabolites.<sup>
<xref ref-type="bibr" rid="bibr80-1933719112446080">80</xref>
</sup> Also, individuals with high levels of CYP450 expression can metabolize 2-ME2 to estrogenic components at elevated rates, an observation especially relevant in postmenopausal women with estrogen-dependent tumors. Therefore, anti-E<sub>2</sub> therapy targeting ER, rather than aromatase inhibitors, should be added to block estrogenic effects of 2-ME2 or its metabolites, without limiting the efficacy of the antiproliferative activity of 2-ME2.<sup>
<xref ref-type="bibr" rid="bibr83-1933719112446080">83</xref>
</sup>
</p>
</sec>
<sec id="section10-1933719112446080">
<title>2-Methoxyestradiol and Endometriosis</title>
<p>As stated in Pathogenesis of Endometriosis section, various hypotheses try to explain the pathogenesis of endometriosis, some of them complementing each other. Sampson’s theory on retrograde menstruation and transplant of endometrial tissue/cells in the peritoneal cavity is perhaps the most widely accepted hypothesis.<sup>
<xref ref-type="bibr" rid="bibr8-1933719112446080">8</xref>
</sup> On the other hand, a state of anoxia has been experimentally shown in endometriotic lesions surgically transplanted during the early stages of transplant and invasion. These findings support the concept that hypoxia is an early event in the development of transplanted endometriotic lesions, which decreases once new vessels have started tissue invasion (<xref ref-type="fig" rid="fig1-1933719112446080">Figure 1</xref>). As discussed in Neoangiogenesis and Endometriosis section, hypoxia is a potent stimulus for the growth of new vessels through the regulation of the HIF-1α/VEGF pathway. In a hypoxic environment, HIF-1α expression is stimulated, which strongly induces VEGF and other proangiogenic gene expression.<sup>
<xref ref-type="bibr" rid="bibr94-1933719112446080">94</xref>
</sup> Following Sampson’s theory, it has been found that the presence of unchanged glandular structures and stromal components is necessary for the invasive potential of endometrial cells and formation of endometriosis.<sup>
<xref ref-type="bibr" rid="bibr107-1933719112446080">107</xref>
</sup> Continuing with the hypothesis for the establishment and growth of all endometriotic lesions, the acquisition of new vessels is a basic requirement to ensure adequate oxygen and nutrient supply. Angiogenesis is dependent on the local balance between proangiogenic cytokines and endogenous angiogenic factors. This scenario is similar to the one found in tumors, where it has been proposed that a balance of these factors leads to an inactive status, in which the number of proliferating cells is the same as the number of cells subject to apoptosis. A change in the proangiogenic phenotype balance leads to tumor growth and metastasis.<sup>
<xref ref-type="bibr" rid="bibr78-1933719112446080">78</xref>
</sup> Many studies in tumors have shown that a high amount of VEGF is present in hypoxic areas, which causes a mitotic stimulus in endothelial cells to proliferate and form new blood vessels.<sup>
<xref ref-type="bibr" rid="bibr78-1933719112446080">78</xref>
</sup> A similar mechanism appears to occur in the pathogenesis of endometriosis.<sup>
<xref ref-type="bibr" rid="bibr21-1933719112446080">21</xref>,<xref ref-type="bibr" rid="bibr108-1933719112446080">108</xref>
</sup>
</p>
<p>It has recently been proposed that angiogenesis suppression is an attractive approach for the treatment of endometriosis.<sup>
<xref ref-type="bibr" rid="bibr18-1933719112446080">18</xref>
</sup> Several groups have demonstrated in animal models that systemic therapy with several angiogenesis inhibitors, such as the 27-amino acid endostatin peptide and the caplostatin derivative TNP-470, is effective in suppressing endometriotic growth.<sup>
<xref ref-type="bibr" rid="bibr18-1933719112446080">18</xref>
</sup> Becker et al used 2-ME2 in their experimental mouse model of endometriosis. They showed that systemic treatment with 2-ME2 for 5 weeks suppresses endometriotic growth in a dose-dependent manner. They suggested that 2-ME2 may be acting both directly and indirectly on endometric tissues. The indirect effect would occur through HIF-1α inhibition, which would lead to suppression of VEGF and other proangiogenic factors, eliminating the stimulus for angiogenesis. The direct effect would occur through the modulation of endothelial cell function. Vascular endothelium growth factor also increases vascular permeability. Therefore, this VEGF action would also decrease by the inhibition of VEGF formation. They hypothesize that 2-ME2 may act to prevent and treat the development of endometriotic lesions, and in humans they suggest that it could be used as an adjuvant therapy to surgery or hormonal treatment of endometriosis.<sup>
<xref ref-type="bibr" rid="bibr34-1933719112446080">34</xref>
</sup> In patients with early stages of the disease, where neoangiogenesis is developing, the use of 2-ME2 could stand alone as a single therapy.</p>
<p>There is also evidence for a strong immune or inflammatory etiology for endometriosis (<xref ref-type="fig" rid="fig1-1933719112446080">Figure 1</xref>); the inflammatory mechanisms involved in endometriosis are thoroughly reviewed by Herington et al.<sup>
<xref ref-type="bibr" rid="bibr109-1933719112446080">109</xref>
</sup> In endometriosis there is an increased concentration of activated macrophages, cytokines, T cells, and B cells.<sup>
<xref ref-type="bibr" rid="bibr27-1933719112446080">27</xref>,<xref ref-type="bibr" rid="bibr110-1933719112446080">110</xref>
<xref ref-type="bibr" rid="bibr111-1933719112446080"/>–<xref ref-type="bibr" rid="bibr112-1933719112446080">112</xref>
</sup> Peritoneal macrophages of women with endometriosis have an increased secretory activity and accentuated activation,<sup>
<xref ref-type="bibr" rid="bibr113-1933719112446080">113</xref>
</sup> and in a mouse experimental model of endometriosis, macrophage activation is involved in the establishment, survival, and spreading of ectopic lesions shed from the endometrium.<sup>
<xref ref-type="bibr" rid="bibr114-1933719112446080">114</xref>
</sup> As shown in <xref ref-type="fig" rid="fig2-1933719112446080">Figure 2</xref>, it is important to highlight the anti-inflammatory actions of 2-ME2 in animal models of rheumatoid arthritis, chronic airway inflammation, and pulmonary fibrosis.<sup>
<xref ref-type="bibr" rid="bibr74-1933719112446080">74</xref>,<xref ref-type="bibr" rid="bibr115-1933719112446080">115</xref>,<xref ref-type="bibr" rid="bibr116-1933719112446080">116</xref>
</sup> The anti-inflammatory actions of 2-ME2 are in part attributed to its antiangiogenic activity.<sup>
<xref ref-type="bibr" rid="bibr74-1933719112446080">74</xref>,<xref ref-type="bibr" rid="bibr115-1933719112446080">115</xref>,<xref ref-type="bibr" rid="bibr116-1933719112446080">116</xref>
</sup> Shand et al<sup>
<xref ref-type="bibr" rid="bibr117-1933719112446080">117</xref>
</sup> reported the novel observation that 2-ME2 regulates anti-inflammatory response in lipopolysaccharide- and interferon-γ-activated J774 mouse macrophage cell line and human blood monocytes. This effect was independent of its antiproliferative or antiangiogenic actions, at doses similar to those having antitumor activity, although they also recognized that the molecular mechanism underlying the direct effects of 2-ME2 on macrophages remains unknown.<sup>
<xref ref-type="bibr" rid="bibr117-1933719112446080">117</xref>,<xref ref-type="bibr" rid="bibr118-1933719112446080">118</xref>
</sup>
</p>
<p>Because the most accepted source of endometrial tissue in the abdominal cavity is retrograde menstruation, a phenomena occurring in over 90% of women, which factor determines the development of this condition in some women? A tentative hypothesis could be associated with changes in estrogen metabolism that lead to a 2-ME2 deficiency (<xref ref-type="fig" rid="fig1-1933719112446080">Figure 1</xref>). The deficiency of this metabolite, which has been shown to be, among others, a natural antiangiogenic molecule, would lead these patients to experience a change in the balance of angiogenic/antiangiogenic factors, favorable to the former, with the prevalence of the inflammatory state along with vascular endothelium dysfunction, exerted through the HIF-1/VEGF axis (<xref ref-type="fig" rid="fig1-1933719112446080">Figure 1</xref>).</p>
<p>The broad-spectrum activity of 2-ME2 also explains the beneficial effects of systemic administration observed by some authors in experimentally induced endometriotic lesions<sup>
<xref ref-type="bibr" rid="bibr34-1933719112446080">34</xref>
</sup>; however, no studies to date have reported successful measurements of 2-ME2 in endometriosis. This pathophysiologic mechanism could be a new hypothesis to explain the development of endometrial lesions and has been well characterized in other pathologies. 2-Methoxyestradiol deficiency has been experimentally implicated in other cardiovascular and renal disease models.<sup>
<xref ref-type="bibr" rid="bibr119-1933719112446080">119</xref>,<xref ref-type="bibr" rid="bibr120-1933719112446080">120</xref>
</sup> For example, in preeclampsia, a pregnancy disease associated with endothelial dysfunction, hypertension, proteinuria, edema, and high fetal morbidity–mortality, there is a 2-ME2 deficiency in animal models. This defect has been attributed to a congenital deficit of COMT. The administration of 2-ME2 to mice with lesions similar to those seen in preeclampsia enabled the recovery from the condition without toxicity.<sup>
<xref ref-type="bibr" rid="bibr121-1933719112446080">121</xref>,<xref ref-type="bibr" rid="bibr122-1933719112446080">122</xref>
</sup> However, the possible adverse effects of 2-ME2 in women of childbearing potential should be considered in matters related to reproduction, such as follicular development and embryonic and fetal development.<sup>
<xref ref-type="bibr" rid="bibr24-1933719112446080">24</xref>
</sup> Little information is available on the possible side effects of antiangiogenic treatment in the context of endometriosis,<sup>
<xref ref-type="bibr" rid="bibr108-1933719112446080">108</xref>
</sup> but adverse effects of antiangiogenic therapy have been reported in ovarian cancer.<sup>
<xref ref-type="bibr" rid="bibr123-1933719112446080">123</xref>
</sup> Several studies on the oral administration of 2-ME2 to humans have been performed, and overall, 2-ME2 appears to have minimal toxicities even when given at high doses, especially in the context of cancer treatment.<sup>
<xref ref-type="bibr" rid="bibr124-1933719112446080">124</xref>
</sup> During the past decade 2-ME2 has received attention due to its anticancer activities, and phase I and II clinical trials revealed that orally administered 2-ME2 is well tolerated by patients, with associated low grade 2 and 3 toxicity.<sup>
<xref ref-type="bibr" rid="bibr124-1933719112446080">124</xref>
</sup> The adverse effects of 2-ME2 are related to its estrogenic effects, including hot flashes, thrombosis, and fluid retention.<sup>
<xref ref-type="bibr" rid="bibr125-1933719112446080">125</xref>
</sup> In another recent study, the dose-limiting toxicities were fatigue, muscle weakness, hypophosphatemia, hyponatremia, anorexia, and increased alanine aminotransferase and γ-glutamyltransferase.<sup>
<xref ref-type="bibr" rid="bibr126-1933719112446080">126</xref>
</sup> However, there is no information on the risk of teratogenic effects of 2-ME2 administrations to humans. On the other hand, the efficacy of antiangiogenic therapies may be limited by the fact that spatiotemporal differences in neovascularization are likely to exist in active endometriotic lesions.<sup>
<xref ref-type="bibr" rid="bibr127-1933719112446080">127</xref>
</sup> This limitation may prove particularly critical for the treatment of certain clinical forms of endometriosis, such as rectovaginal endometriotic nodules, which contain a high proportion of mature vessels.<sup>
<xref ref-type="bibr" rid="bibr21-1933719112446080">21</xref>
</sup> However, as reviewed above, inflammation is an important component in the pathophysiology of endometriosis<sup>
<xref ref-type="bibr" rid="bibr109-1933719112446080">109</xref>
</sup> and anti-inflammatory actions of 2-ME2 independent on angiogenesis could result from reciprocating or complementary ways to the well-known effects on cell proliferation and blood vessel development<sup>
<xref ref-type="bibr" rid="bibr117-1933719112446080">117</xref>
</sup> (<xref ref-type="fig" rid="fig2-1933719112446080">Figure 2</xref>). Retrograde menstruation debris could activate the first line of immune defense, the peritoneal macrophages, which respond by producing proinflammatory cytokines, which could favor the establishment of endometriotic tissue.<sup>
<xref ref-type="bibr" rid="bibr109-1933719112446080">109</xref>
</sup> Recently it has been found that 2-ME is active in inhibiting the production of proinflammatory cytokines by macrophages in vitro and in vivo.<sup>
<xref ref-type="bibr" rid="bibr128-1933719112446080">128</xref>
</sup>
</p>
</sec>
<sec id="section11-1933719112446080">
<title>Conclusions</title>
<p>2-Methoxyestradiol is an active estrogen metabolite with antitumor activity in several cancer cell lines. In addition to this action, 2-ME2 displays antiangiogenic activity and, therefore, blocks the formation of new blood vessels in neoplastic lesions, including endometriosis. 2-Methoxyestradiol also has a wide anti-inflammatory action, which in part is dependent on its antiangiogenesis activity. The combination of antiangiogenic therapy with anti-inflammatory therapy in endometriosis is currently an area of interest and intense research activity, and the use of 2-ME2 as a single therapeutic compound is a promising approach. Although the side effects of 2-ME2 therapy, especially the E<sub>2</sub>-like activity of 2-ME2 or its metabolites particularly in reproductive fertile woman, may also need to be considered in E<sub>2</sub>-dependent pathologies, such as endometriosis or breast cancer. Therefore, there is an urgent need for new compounds derived from 2-ME2, with little or no E<sub>2</sub> activity or metabolism to E<sub>2</sub>-like molecules and with better pharmacokinetics and potency. Such compounds will emerge as potential new treatments for endometriosis. The data summarized in this review lead to 2 main concepts: the possible participation of 2-ME2 in the pathophysiology of endometriosis and the use of 2-ME2 as a potential therapeutic agent to treat endometriosis.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="other" id="fn1-1933719112446080">
<label>Authors’ Note</label>
<p>The authors Francisco Machado-Linde and Pablo Pelegrin contributed equally to this work.</p>
</fn>
<fn fn-type="conflict" id="fn2-1933719112446080">
<label>Declaration of Conflicting Interests</label>
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn3-1933719112446080">
<label>Funding</label>
<p>The authors received no financial support for the research, authorship, and/or publication of this article. </p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1933719112446080">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berkley</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Rapkin</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Papka</surname>
<given-names>RE</given-names>
</name>
</person-group>. <article-title>The pains of endometriosis</article-title>. <source>Science</source>. <year>2005</year>;<volume>308</volume>(<issue>5728</issue>):<fpage>1587</fpage>–<lpage>1589</lpage>.</citation>
</ref>
<ref id="bibr2-1933719112446080">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kennedy</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bergqvist</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chapron</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group> <article-title>ESHRE guideline for the diagnosis and treatment of endometriosis</article-title>. <source>Hum Reprod</source>. <year>2005</year>;<volume>20</volume>(<issue>10</issue>):<fpage>2698</fpage>–<lpage>2704</lpage>.</citation>
</ref>
<ref id="bibr3-1933719112446080">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Somigliana</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Vigano</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Parazzini</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Stoppelli</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Giambattista</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Vercellini</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Association between endometriosis and cancer: a comprehensive review and a critical analysis of clinical and epidemiological evidence</article-title>. <source>Gynecol Oncol</source>. <year>2006</year>;<volume>101</volume>(<issue>2</issue>):<fpage>331</fpage>–<lpage>341</lpage>.</citation>
</ref>
<ref id="bibr4-1933719112446080">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meyer</surname>
<given-names>W</given-names>
</name>
</person-group>. <article-title>Über eine adenomatöse Wucherung der Serosa in einer Bauchnarbe</article-title>. <source>Z Geburtshilfe Gynakol</source>. <year>1903</year>;<volume>49</volume>:<fpage>32</fpage>–<lpage>41</lpage>.</citation>
</ref>
<ref id="bibr5-1933719112446080">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Halban</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Hysteroadenosis metastatica</article-title>. <source>Wien Klin Wochenschr</source>. <year>1924</year>;<volume>37</volume>:<fpage>1205</fpage>–<lpage>1206</lpage>.</citation>
</ref>
<ref id="bibr6-1933719112446080">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Simpson</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Elias</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Malinak</surname>
<given-names>LR</given-names>
</name>
<name>
<surname>Buttram</surname>
<given-names>VC</given-names>
<suffix>Jr</suffix>
</name>
</person-group>. <article-title>Heritable aspects of endometriosis. I. Genetic studies</article-title>. <source>Am J Obstet Gynecol</source>. <year>1980</year>;<volume>137</volume>(<issue>3</issue>):<fpage>327</fpage>–<lpage>331</lpage>.</citation>
</ref>
<ref id="bibr7-1933719112446080">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zondervan</surname>
<given-names>KT</given-names>
</name>
<name>
<surname>Weeks</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Colman</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group> <article-title>Familial aggregation of endometriosis in a large pedigree of rhesus macaques</article-title>. <source>Hum Reprod</source>. <year>2004</year>;<volume>19</volume>(<issue>2</issue>):<fpage>448</fpage>–<lpage>455</lpage>.</citation>
</ref>
<ref id="bibr8-1933719112446080">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sampson</surname>
<given-names>JA</given-names>
</name>
</person-group>. <article-title>Metastatic or embolic endometriosis, due to the menstrual dissemination of endometrial tissue into the venous circulation</article-title>. <source>Am J Pathol</source>. <year>1927</year>;<volume>3</volume>(<issue>2</issue>):<fpage>93</fpage>–<lpage>110</lpage>.</citation>
</ref>
<ref id="bibr9-1933719112446080">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taylor</surname>
<given-names>RN</given-names>
</name>
<name>
<surname>Lebovic</surname>
<given-names>DI</given-names>
</name>
<name>
<surname>Mueller</surname>
<given-names>MD</given-names>
</name>
</person-group>. <article-title>Angiogenic factors in endometriosis</article-title>. <source>Ann N Y Acad Sci</source>. <year>2002</year>;<volume>955</volume>:<fpage>89</fpage>–<lpage>100</lpage>.</citation>
</ref>
<ref id="bibr10-1933719112446080">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dunselman</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Groothuis</surname>
<given-names>PG</given-names>
</name>
</person-group>. <article-title>Etiology of endometriosis: hypotheses and facts</article-title>. <source>Gynecol Obstet Invest</source>. <year>2004</year>;<volume>57</volume>(<issue>1</issue>):<fpage>42</fpage>–<lpage>43</lpage>.</citation>
</ref>
<ref id="bibr11-1933719112446080">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Halme</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hammond</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Hulka</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Raj</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Talbert</surname>
<given-names>LM</given-names>
</name>
</person-group>. <article-title>Retrograde menstruation in healthy women and in patients with endometriosis</article-title>. <source>Obstet Gynecol</source>. <year>1984</year>;<volume>64</volume>(<issue>2</issue>):<fpage>151</fpage>–<lpage>154</lpage>.</citation>
</ref>
<ref id="bibr12-1933719112446080">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rohan</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Fernandez</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Udagawa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>D'Amato</surname>
<given-names>RJ</given-names>
</name>
</person-group>. <article-title>Genetic heterogeneity of angiogenesis in mice</article-title>. <source>FASEB J</source>. <year>2000</year>;<volume>14</volume>(<issue>7</issue>):<fpage>871</fpage>–<lpage>876</lpage>.</citation>
</ref>
<ref id="bibr13-1933719112446080">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>SK</given-names>
</name>
</person-group>. <article-title>Angiogenesis, vascular endothelial growth factor and the endometrium</article-title>. <source>Hum Reprod Update</source>. <year>1998</year>;<volume>4</volume>(<issue>5</issue>):<fpage>509</fpage>–<lpage>519</lpage>.</citation>
</ref>
<ref id="bibr14-1933719112446080">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gordon</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Shifren</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Foulk</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>RN</given-names>
</name>
<name>
<surname>Jaffe</surname>
<given-names>RB</given-names>
</name>
</person-group>. <article-title>Angiogenesis in the human female reproductive tract</article-title>. <source>Obstet Gynecol Surv</source>. <year>1995</year>;<volume>50</volume>(<issue>9</issue>):<fpage>688</fpage>–<lpage>697</lpage>.</citation>
</ref>
<ref id="bibr15-1933719112446080">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Folkman</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Angiogenesis in cancer, vascular, rheumatoid and other disease</article-title>. <source>Nat Med</source>. <year>1995</year>;<volume>1</volume>(<issue>1</issue>):<fpage>27</fpage>–<lpage>31</lpage>.</citation>
</ref>
<ref id="bibr16-1933719112446080">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Healy</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Hii</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wingfield</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Angiogenesis: a new theory for endometriosis</article-title>. <source>Hum Reprod Update</source>. <year>1998</year>;<volume>4</volume>(<issue>5</issue>):<fpage>736</fpage>–<lpage>740</lpage>.</citation>
</ref>
<ref id="bibr17-1933719112446080">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Folkman</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Tumor angiogenesis: therapeutic implications</article-title>. <source>N Engl J Med</source>. <year>1971</year>;<volume>285</volume>(<issue>21</issue>):<fpage>1182</fpage>–<lpage>1186</lpage>.</citation>
</ref>
<ref id="bibr18-1933719112446080">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Becker</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>D'Amato</surname>
<given-names>RJ</given-names>
</name>
</person-group>. <article-title>Angiogenesis and antiangiogenic therapy in endometriosis</article-title>. <source>Microvasc Res</source>. <year>2007</year>;<volume>74</volume>(<issue>2-3</issue>):<fpage>121</fpage>–<lpage>130</lpage>.</citation>
</ref>
<ref id="bibr19-1933719112446080">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nisolle</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Casanas-Roux</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Anaf</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Mine</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Donnez</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Morphometric study of the stromal vascularization in peritoneal endometriosis</article-title>. <source>Fertil Steril</source>. <year>1993</year>;<volume>59</volume>(<issue>3</issue>):<fpage>681</fpage>–<lpage>684</lpage>.</citation>
</ref>
<ref id="bibr20-1933719112446080">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taylor</surname>
<given-names>RN</given-names>
</name>
<name>
<surname>Ryan</surname>
<given-names>IP</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Hornung</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Shifren</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Tseng</surname>
<given-names>JF</given-names>
</name>
</person-group>. <article-title>Angiogenesis and macrophage activation in endometriosis</article-title>. <source>Ann N Y Acad Sci</source>. <year>1997</year>;<volume>828</volume>:<fpage>194</fpage>–<lpage>207</lpage>.</citation>
</ref>
<ref id="bibr21-1933719112446080">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Groothuis</surname>
<given-names>PG</given-names>
</name>
<name>
<surname>Nap</surname>
<given-names>AW</given-names>
</name>
<name>
<surname>Winterhager</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Grummer</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Vascular development in endometriosis</article-title>. <source>Angiogenesis</source>. <year>2005</year>;<volume>8</volume>(<issue>2</issue>):<fpage>147</fpage>–<lpage>156</lpage>.</citation>
</ref>
<ref id="bibr22-1933719112446080">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McLaren</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Vascular endothelial growth factor and endometriotic angiogenesis</article-title>. <source>Hum Reprod Update</source>. <year>2000</year>;<volume>6</volume>(<issue>1</issue>):<fpage>45</fpage>–<lpage>55</lpage>.</citation>
</ref>
<ref id="bibr23-1933719112446080">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsuzaki</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Canis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Murakami</surname>
<given-names>T</given-names>
</name>
</person-group>
<etal/> <article-title>Immunohistochemical analysis of the role of angiogenic status in the vasculature of peritoneal endometriosis</article-title>. <source>Fertil Steril</source>. <year>2001</year>;<volume>76</volume>(<issue>4</issue>):<fpage>712</fpage>–<lpage>716</lpage>.</citation>
</ref>
<ref id="bibr24-1933719112446080">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Langendonckt</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Donnez</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Defrere</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dunselman</surname>
<given-names>GA</given-names>
</name>
<name>
<surname>Groothuis</surname>
<given-names>PG</given-names>
</name>
</person-group>. <article-title>Antiangiogenic and vascular-disrupting agents in endometriosis: pitfalls and promises</article-title>. <source>Mol Hum Reprod</source>. <year>2008</year>;<volume>14</volume>(<issue>5</issue>):<fpage>259</fpage>–<lpage>268</lpage>.</citation>
</ref>
<ref id="bibr25-1933719112446080">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oosterlynck</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Meuleman</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sobis</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Vandeputte</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Koninckx</surname>
<given-names>PR</given-names>
</name>
</person-group>. <article-title>Angiogenic activity of peritoneal fluid from women with endometriosis</article-title>. <source>Fertil Steril</source>. <year>1993</year>;<volume>59</volume>(<issue>4</issue>):<fpage>778</fpage>–<lpage>782</lpage>.</citation>
</ref>
<ref id="bibr26-1933719112446080">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Lei</surname>
<given-names>HY</given-names>
</name>
<name>
<surname>Wing</surname>
<given-names>LY</given-names>
</name>
</person-group>. <article-title>Neutrophils and macrophages promote angiogenesis in the early stage of endometriosis in a mouse model</article-title>. <source>Endocrinology</source>. <year>2006</year>;<volume>147</volume>(<issue>3</issue>):<fpage>1278</fpage>–<lpage>1286</lpage>.</citation>
</ref>
<ref id="bibr27-1933719112446080">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akoum</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Metz</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Beaumont</surname>
<given-names>MC</given-names>
</name>
</person-group>. <article-title>Spontaneous and stimulated secretion of monocyte chemotactic protein-1 and macrophage migration inhibitory factor by peritoneal macrophages in women with and without endometriosis</article-title>. <source>Fertil Steril</source>. <year>2002</year>;<volume>77</volume>(<issue>5</issue>):<fpage>989</fpage>–<lpage>994</lpage>.</citation>
</ref>
<ref id="bibr28-1933719112446080">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McLaren</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Prentice</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Charnock-Jones</surname>
<given-names>DS</given-names>
</name>
</person-group>
<etal/> <article-title>Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids</article-title>. <source>J Clin Invest</source>. <year>1996</year>;<volume>98</volume>(<issue>2</issue>):<fpage>482</fpage>–<lpage>489</lpage>.</citation>
</ref>
<ref id="bibr29-1933719112446080">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dvorak</surname>
<given-names>HF</given-names>
</name>
</person-group>. <article-title>Discovery of vascular permeability factor (VPF)</article-title>. <source>Exp Cell Res</source>. <year>2006</year>;<volume>312</volume>(<issue>5</issue>):<fpage>522</fpage>–<lpage>526</lpage>.</citation>
</ref>
<ref id="bibr30-1933719112446080">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roskoski</surname>
<given-names>R</given-names>
<suffix>Jr</suffix>
</name>
</person-group>. <article-title>Vascular endothelial growth factor (VEGF) signaling in tumor progression</article-title>. <source>Crit Rev Oncol Hematol</source>. <year>2007</year>;<volume>62</volume>(<issue>3</issue>):<fpage>179</fpage>–<lpage>213</lpage>.</citation>
</ref>
<ref id="bibr31-1933719112446080">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shifren</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Tseng</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Zaloudek</surname>
<given-names>CJ</given-names>
</name>
</person-group>
<etal/> <article-title>Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1996</year>;<volume>81</volume>(<issue>8</issue>):<fpage>3112</fpage>–<lpage>3118</lpage>.</citation>
</ref>
<ref id="bibr32-1933719112446080">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shweiki</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Itin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Soffer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Keshet</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis</article-title>. <source>Nature</source>. <year>1992</year>;<volume>359</volume>(<issue>6398</issue>):<fpage>843</fpage>–<lpage>845</lpage>.</citation>
</ref>
<ref id="bibr33-1933719112446080">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hirota</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Semenza</surname>
<given-names>GL</given-names>
</name>
</person-group>. <article-title>Regulation of angiogenesis by hypoxia-inducible factor 1</article-title>. <source>Crit Rev Oncol Hematol</source>. <year>2006</year>;<volume>59</volume>(<issue>1</issue>):<fpage>15</fpage>–<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr34-1933719112446080">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Becker</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Rohwer</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Funakoshi</surname>
<given-names>T</given-names>
</name>
</person-group>
<etal/> <article-title>2-methoxyestradiol inhibits hypoxia-inducible factor-1{alpha} and suppresses growth of lesions in a mouse model of endometriosis</article-title>. <source>Am J Pathol</source>. <year>2008</year>;<volume>172</volume>(<issue>2</issue>):<fpage>534</fpage>–<lpage>544</lpage>.</citation>
</ref>
<ref id="bibr35-1933719112446080">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>KF</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Lgu</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>SJ</given-names>
</name>
</person-group>. <article-title>Aberrant expression of leptin in human endometriotic stromal cells is induced by elevated levels of hypoxia inducible factor-1alpha</article-title>. <source>Am J Pathol</source>. <year>2007</year>;<volume>170</volume>(<issue>2</issue>):<fpage>590</fpage>–<lpage>598</lpage>.</citation>
</ref>
<ref id="bibr36-1933719112446080">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hyder</surname>
<given-names>SM</given-names>
</name>
</person-group>. <article-title>Sex-steroid regulation of vascular endothelial growth factor in breast cancer</article-title>. <source>Endocr Relat Cancer</source>. <year>2006</year>;<volume>13</volume>(<issue>3</issue>):<fpage>667</fpage>–<lpage>687</lpage>.</citation>
</ref>
<ref id="bibr37-1933719112446080">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kazi</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Molitoris</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Koos</surname>
<given-names>RD</given-names>
</name>
</person-group>. <article-title>Estrogen rapidly activates the PI3K/AKT pathway and hypoxia-inducible factor 1 and induces vascular endothelial growth factor A expression in luminal epithelial cells of the rat uterus</article-title>. <source>Biol Reprod</source>. <year>2009</year>;<volume>81</volume>(<issue>2</issue>):<fpage>378</fpage>–<lpage>387</lpage>.</citation>
</ref>
<ref id="bibr38-1933719112446080">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chennazhi</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Nayak</surname>
<given-names>NR</given-names>
</name>
</person-group>. <article-title>Regulation of angiogenesis in the primate endometrium: vascular endothelial growth factor</article-title>. <source>Semin Reprod Med</source>. <year>2009</year>;<volume>27</volume>(<issue>1</issue>):<fpage>80</fpage>–<lpage>89</lpage>.</citation>
</ref>
<ref id="bibr39-1933719112446080">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dizerega</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Barber</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Hodgen</surname>
<given-names>GD</given-names>
</name>
</person-group>. <article-title>Endometriosis: role of ovarian steroids in initiation, maintenance, and suppression</article-title>. <source>Fertil Steril</source>. <year>1980</year>;<volume>33</volume>(<issue>6</issue>):<fpage>649</fpage>–<lpage>653</lpage>.</citation>
</ref>
<ref id="bibr40-1933719112446080">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rizner</surname>
<given-names>TL</given-names>
</name>
</person-group>. <article-title>Estrogen metabolism and action in endometriosis</article-title>. <source>Mol Cell Endocrinol</source>. <year>2009</year>;<volume>307</volume>(<issue>1-2</issue>):<fpage>8</fpage>–<lpage>18</lpage>.</citation>
</ref>
<ref id="bibr41-1933719112446080">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hyder</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Nawaz</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Chiappetta</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Stancel</surname>
<given-names>GM</given-names>
</name>
</person-group>. <article-title>Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor</article-title>. <source>Cancer Res</source>. <year>2000</year>;<volume>60</volume>(<issue>12</issue>):<fpage>3183</fpage>–<lpage>3190</lpage>.</citation>
</ref>
<ref id="bibr42-1933719112446080">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bukulmez</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Hardy</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>Carr</surname>
<given-names>BR</given-names>
</name>
<name>
<surname>Word</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Mendelson</surname>
<given-names>CR</given-names>
</name>
</person-group>. <article-title>Inflammatory status influences aromatase and steroid receptor expression in endometriosis</article-title>. <source>Endocrinology</source>. <year>2008</year>;<volume>149</volume>(<issue>3</issue>):<fpage>1190</fpage>–<lpage>1204</lpage>.</citation>
</ref>
<ref id="bibr43-1933719112446080">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noble</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Takayama</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Zeitoun</surname>
<given-names>KM</given-names>
</name>
</person-group>
<etal/> <article-title>Prostaglandin E2 stimulates aromatase expression in endometriosis-derived stromal cells</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1997</year>;<volume>82</volume>(<issue>2</issue>):<fpage>600</fpage>–<lpage>606</lpage>.</citation>
</ref>
<ref id="bibr44-1933719112446080">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sawaoka</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tsuji</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tsujii</surname>
<given-names>M</given-names>
</name>
</person-group>
<etal/> <article-title>Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo</article-title>. <source>Lab Invest</source>. <year>1999</year>;<volume>79</volume>(<issue>12</issue>):<fpage>1469</fpage>–<lpage>1477</lpage>.</citation>
</ref>
<ref id="bibr45-1933719112446080">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Santanam</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Parthasarathy</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Macrophages, oxidation, and endometriosis</article-title>. <source>Ann N Y Acad Sci</source>. <year>2002</year>;<volume>955</volume>:<fpage>183</fpage>–<lpage>198</lpage>.</citation>
</ref>
<ref id="bibr46-1933719112446080">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taylor</surname>
<given-names>RN</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Torres</surname>
<given-names>PB</given-names>
</name>
</person-group>
<etal/> <article-title>Mechanistic and therapeutic implications of angiogenesis in endometriosis</article-title>. <source>Reprod Sci</source>. <year>2009</year>;<volume>16</volume>(<issue>2</issue>):<fpage>140</fpage>–<lpage>146</lpage>.</citation>
</ref>
<ref id="bibr47-1933719112446080">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Missmer</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Cramer</surname>
<given-names>DW</given-names>
</name>
</person-group>. <article-title>The epidemiology of endometriosis</article-title>. <source>Obstet Gynecol Clin North Am</source>. <year>2003</year>;<volume>30</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>19</lpage>.</citation>
</ref>
<ref id="bibr48-1933719112446080">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shaw</surname>
<given-names>RW</given-names>
</name>
</person-group>. <article-title>The role of GnRH analogues in the treatment of endometriosis</article-title>. <source>Br J Obstet Gynaecol</source>. <year>1992</year>;<volume>99</volume> (<issue>suppl 7</issue>):<fpage>9</fpage>–<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr49-1933719112446080">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shakiba</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bena</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>McGill</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Minger</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Falcone</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Surgical treatment of endometriosis: a 7-year follow-up on the requirement for further surgery</article-title>. <source>Obstet Gynecol</source>. <year>2008</year>;<volume>111</volume>(<issue>6</issue>):<fpage>1285</fpage>–<lpage>1292</lpage>.</citation>
</ref>
<ref id="bibr50-1933719112446080">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giannarini</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Scott</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Moro</surname>
<given-names>U</given-names>
</name>
</person-group>
<etal/> <article-title>Cystic endometriosis of the epididymis</article-title>. <source>Urology</source>. <year>2006</year>;<volume>68</volume>(<issue>1</issue>):<fpage>203</fpage>. <fpage>e1</fpage>–<lpage>e3</lpage>.</citation>
</ref>
<ref id="bibr51-1933719112446080">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinkert</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Catlow</surname>
<given-names>CE</given-names>
</name>
<name>
<surname>Straus</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Endometriosis of the urinary bladder in a man with prostatic carcinoma</article-title>. <source>Cancer</source>. <year>1979</year>;<volume>43</volume>(<issue>4</issue>):<fpage>1562</fpage>–<lpage>1567</lpage>.</citation>
</ref>
<ref id="bibr52-1933719112446080">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takahashi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nagata</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kitao</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Clinical usefulness of determination of estradiol level in the menstrual blood for patients with endometriosis</article-title>. <source>Nihon Sanka Fujinka Gakkai Zasshi</source>. <year>1989</year>;<volume>41</volume>(<issue>11</issue>):<fpage>1849</fpage>–<lpage>1850</lpage>.</citation>
</ref>
<ref id="bibr53-1933719112446080">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noble</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Simpson</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Johns</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bulun</surname>
<given-names>SE</given-names>
</name>
</person-group>. <article-title>Aromatase expression in endometriosis</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1996</year>;<volume>81</volume>(<issue>1</issue>):<fpage>174</fpage>–<lpage>179</lpage>.</citation>
</ref>
<ref id="bibr54-1933719112446080">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeitoun</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Takayama</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sasano</surname>
<given-names>H</given-names>
</name>
</person-group>
<etal/> <article-title>Deficient 17beta-hydroxysteroid dehydrogenase type 2 expression in endometriosis: failure to metabolize 17beta-estradiol</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1998</year>;<volume>83</volume>(<issue>12</issue>):<fpage>4474</fpage>–<lpage>4480</lpage>.</citation>
</ref>
<ref id="bibr55-1933719112446080">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smuc</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hevir</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ribic-Pucelj</surname>
<given-names>M</given-names>
</name>
</person-group>
<etal/> <article-title>Disturbed estrogen and progesterone action in ovarian endometriosis</article-title>. <source>Mol Cell Endocrinol</source>. <year>2009</year>;<volume>301</volume>(<issue>1-2</issue>):<fpage>59</fpage>–<lpage>64</lpage>.</citation>
</ref>
<ref id="bibr56-1933719112446080">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mannisto</surname>
<given-names>PT</given-names>
</name>
<name>
<surname>Kaakkola</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors</article-title>. <source>Pharmacol Rev</source>. <year>1999</year>;<volume>51</volume>(<issue>4</issue>):<fpage>593</fpage>–<lpage>628</lpage>.</citation>
</ref>
<ref id="bibr57-1933719112446080">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Berg</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Sonsalla</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kuss</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Concentrations of 2-methoxyoestrogens in human serum measured by a heterologous immunoassay with an 125I-labelled ligand</article-title>. <source>Acta Endocrinol (Copenh)</source>. <year>1983</year>;<volume>103</volume>(<issue>2</issue>):<fpage>282</fpage>–<lpage>288</lpage>.</citation>
</ref>
<ref id="bibr58-1933719112446080">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Longcope</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Flood</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Femino</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>KI</given-names>
</name>
</person-group>. <article-title>Metabolism of 2-methoxyestrone in normal men</article-title>. <source>J Clin Endocrinol Metab</source>. <year>1983</year>;<volume>57</volume>(<issue>2</issue>):<fpage>277</fpage>–<lpage>282</lpage>.</citation>
</ref>
<ref id="bibr59-1933719112446080">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ireson</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Chander</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Purohit</surname>
<given-names>A</given-names>
</name>
</person-group>
<etal/> <article-title>Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents</article-title>. <source>Br J Cancer</source>. <year>2004</year>;<volume>90</volume>(<issue>4</issue>):<fpage>932</fpage>–<lpage>937</lpage>.</citation>
</ref>
<ref id="bibr60-1933719112446080">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sweeney</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Yiannoutsos</surname>
<given-names>C</given-names>
</name>
</person-group>
<etal/> <article-title>A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer</article-title>. <source>Clin Cancer Res</source>. <year>2005</year>;<volume>11</volume>(<issue>18</issue>):<fpage>6625</fpage>–<lpage>6633</lpage>.</citation>
</ref>
<ref id="bibr61-1933719112446080">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>You</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Xiang</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>An efficient, practical synthesis of 2-methoxyestradiol</article-title>. <source>Steroids</source>. <year>2010</year>;<volume>75</volume>(<issue>1</issue>):<fpage>53</fpage>–<lpage>56</lpage>.</citation>
</ref>
<ref id="bibr62-1933719112446080">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mueck</surname>
<given-names>AO</given-names>
</name>
<name>
<surname>Seeger</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>2-Methoxyestradiol—biology and mechanism of action</article-title>. <source>Steroids</source>. <year>2010</year>;<volume>75</volume>(<issue>10</issue>):<fpage>625</fpage>–<lpage>631</lpage>.</citation>
</ref>
<ref id="bibr63-1933719112446080">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>TC</given-names>
</name>
</person-group>
<etal/> <article-title>Antiproliferative effects of 2-methoxyestradiol alone and in combination with chemotherapeutic agents on human endometrial cancer cells</article-title>. <source>Eur J Gynaecol Oncol</source>. <year>2009</year>;<volume>30</volume>(<issue>3</issue>):<fpage>275</fpage>–<lpage>280</lpage>.</citation>
</ref>
<ref id="bibr64-1933719112446080">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>ZJ</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>BT</given-names>
</name>
</person-group>. <article-title>Concentration-dependent mitogenic and antiproliferative actions of 2-methoxyestradiol in estrogen receptor-positive human breast cancer cells</article-title>. <source>J Steroid Biochem Mol Biol</source>. <year>2004</year>;<volume>88</volume>(<issue>3</issue>):<fpage>265</fpage>–<lpage>275</lpage>.</citation>
</ref>
<ref id="bibr65-1933719112446080">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tagg</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Foster</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Leese</surname>
<given-names>MP</given-names>
</name>
</person-group>
<etal/> <article-title>2-Methoxyoestradiol-3,17-O,O-bis-sulphamate and 2-deoxy-D-glucose in combination: a potential treatment for breast and prostate cancer</article-title>. <source>Br J Cancer</source>. <year>2008</year>;<volume>99</volume>(<issue>11</issue>):<fpage>1842</fpage>–<lpage>1848</lpage>.</citation>
</ref>
<ref id="bibr66-1933719112446080">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seegers</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Aveling</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Van Aswegen</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Cross</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Koch</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Joubert</surname>
<given-names>WS</given-names>
</name>
</person-group>. <article-title>The cytotoxic effects of estradiol-17 beta, catecholestradiols and methoxyestradiols on dividing MCF-7 and HeLa cells</article-title>. <source>J Steroid Biochem</source>. <year>1989</year>;<volume>32</volume>(<issue>6</issue>):<fpage>797</fpage>–<lpage>809</lpage>.</citation>
</ref>
<ref id="bibr67-1933719112446080">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barchiesi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Gillespie</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Zacharia</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Fingerle</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dubey</surname>
<given-names>RK</given-names>
</name>
</person-group>. <article-title>Methoxyestradiols mediate estradiol-induced antimitogenesis in human aortic SMCs</article-title>. <source>Hypertension</source>. <year>2002</year>;<volume>39</volume>(<issue>4</issue>):<fpage>874</fpage>–<lpage>879</lpage>.</citation>
</ref>
<ref id="bibr68-1933719112446080">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sutherland</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Hughes</surname>
<given-names>RA</given-names>
</name>
</person-group>
<etal/> <article-title>2-Methoxyestradiol--a unique blend of activities generating a new class of anti-tumour/anti-inflammatory agents</article-title>. <source>Drug Discov Today</source>. <year>2007</year>;<volume>12</volume>(<issue>13-14</issue>):<fpage>577</fpage>–<lpage>584</lpage>.</citation>
</ref>
<ref id="bibr69-1933719112446080">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barchiesi</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Fingerle</surname>
<given-names>J</given-names>
</name>
</person-group>
<etal/> <article-title>2-Methoxyestradiol, an estradiol metabolite, inhibits neointima formation and smooth muscle cell growth via double blockade of the cell cycle</article-title>. <source>Circ Res</source>. <year>2006</year>;<volume>99</volume>(<issue>3</issue>):<fpage>266</fpage>–<lpage>274</lpage>.</citation>
</ref>
<ref id="bibr70-1933719112446080">
<label>70</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Salama</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Nasr</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Dubey</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Al-Hendy</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Estrogen metabolite 2-methoxyestradiol induces apoptosis and inhibits cell proliferation and collagen production in rat and human leiomyoma cells: a potential medicinal treatment for uterine fibroids</article-title>. <source>J Soc Gynecol Investig</source>. <year>2006</year>;<volume>13</volume>(<issue>8</issue>):<fpage>542</fpage>–<lpage>550</lpage>.</citation>
</ref>
<ref id="bibr71-1933719112446080">
<label>71</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>D'Amato</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Flynn</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Folkman</surname>
<given-names>J</given-names>
</name>
</person-group>, <article-title>Hamel E. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1994</year>;<volume>91</volume>(<issue>9</issue>):<fpage>3964</fpage>–<lpage>3968</lpage>.</citation>
</ref>
<ref id="bibr72-1933719112446080">
<label>72</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dubey</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>EK</given-names>
</name>
</person-group>. <article-title>Estrogen-induced cardiorenal protection: potential cellular, biochemical, and molecular mechanisms</article-title>. <source>Am J Physiol Renal Physiol</source>. <year>2001</year>;<volume>280</volume>(<issue>3</issue>):<fpage>F365</fpage>–<lpage>F388</lpage>.</citation>
</ref>
<ref id="bibr73-1933719112446080">
<label>73</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nishigaki</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Sasaguri</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yagi</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Anti-proliferative effect of 2-methoxyestradiol on cultured smooth muscle cells from rabbit aorta</article-title>. <source>Atherosclerosis</source>. <year>1995</year>;<volume>113</volume>(<issue>2</issue>):<fpage>167</fpage>–<lpage>170</lpage>.</citation>
</ref>
<ref id="bibr74-1933719112446080">
<label>74</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huerta-Yepez</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Baay-Guzman</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Garcia-Zepeda</surname>
<given-names>R</given-names>
</name>
</person-group>
<etal/> <article-title>2-Methoxyestradiol (2-ME) reduces the airway inflammation and remodeling in an experimental mouse model</article-title>. <source>Clin Immunol</source>. <year>2008</year>;<volume>129</volume>(<issue>2</issue>):<fpage>313</fpage>–<lpage>324</lpage>.</citation>
</ref>
<ref id="bibr75-1933719112446080">
<label>75</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laurent</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nicco</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Chereau</surname>
<given-names>C</given-names>
</name>
</person-group>
<etal/> <article-title>Controlling tumor growth by modulating endogenous production of reactive oxygen species</article-title>. <source>Cancer Res</source>. <year>2005</year>;<volume>65</volume>(<issue>3</issue>):<fpage>948</fpage>–<lpage>956</lpage>.</citation>
</ref>
<ref id="bibr76-1933719112446080">
<label>76</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dubey</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Tofovic</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>EK</given-names>
</name>
</person-group>. <article-title>Cardiovascular pharmacology of estradiol metabolites</article-title>. <source>J Pharmacol Exp Ther</source>. <year>2004</year>;<volume>308</volume>(<issue>2</issue>):<fpage>403</fpage>–<lpage>409</lpage>.</citation>
</ref>
<ref id="bibr77-1933719112446080">
<label>77</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dubey</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Tyurina</surname>
<given-names>YY</given-names>
</name>
<name>
<surname>Tyurin</surname>
<given-names>VA</given-names>
</name>
</person-group>
<etal/> <article-title>Estrogen and tamoxifen metabolites protect smooth muscle cell membrane phospholipids against peroxidation and inhibit cell growth</article-title>. <source>Circ Res</source>. <year>1999</year>;<volume>84</volume>(<issue>2</issue>):<fpage>229</fpage>–<lpage>239</lpage>.</citation>
</ref>
<ref id="bibr78-1933719112446080">
<label>78</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dubey</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>EK</given-names>
</name>
</person-group>. <article-title>Potential vascular actions of 2-methoxyestradiol</article-title>. <source>Trends Endocrinol Metab</source>. <year>2009</year>;<volume>20</volume>(<issue>8</issue>):<fpage>374</fpage>–<lpage>379</lpage>.</citation>
</ref>
<ref id="bibr79-1933719112446080">
<label>79</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gui</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>XL</given-names>
</name>
</person-group>. <article-title>2-Methoxyestradiol induces cell cycle arrest and mitotic cell apoptosis in human vascular smooth muscle cells</article-title>. <source>Hypertension</source>. <year>2006</year>;<volume>47</volume>(<issue>2</issue>):<fpage>271</fpage>–<lpage>280</lpage>.</citation>
</ref>
<ref id="bibr80-1933719112446080">
<label>80</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dawling</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Roodi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Parl</surname>
<given-names>FF</given-names>
</name>
</person-group>. <article-title>Methoxyestrogens exert feedback inhibition on cytochrome P450 1A1 and 1B1</article-title>. <source>Cancer Res</source>. <year>2003</year>;<volume>63</volume>(<issue>12</issue>):<fpage>3127</fpage>–<lpage>3132</lpage>.</citation>
</ref>
<ref id="bibr81-1933719112446080">
<label>81</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fulda</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Debatin</surname>
<given-names>KM</given-names>
</name>
</person-group>. <article-title>Apoptosis pathways: turned on their heads?</article-title> <source>Drug Resist Updat</source>. <year>2003</year>;<volume>6</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>3</lpage>.</citation>
</ref>
<ref id="bibr82-1933719112446080">
<label>82</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>LaVallee</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Zhan</surname>
<given-names>XH</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>MS</given-names>
</name>
</person-group>
<etal/> <article-title>2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway</article-title>. <source>Cancer Res</source>. <year>2003</year>;<volume>63</volume>(<issue>2</issue>):<fpage>468</fpage>–<lpage>475</lpage>.</citation>
</ref>
<ref id="bibr83-1933719112446080">
<label>83</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mooberry</surname>
<given-names>SL</given-names>
</name>
</person-group>. <article-title>Mechanism of action of 2-methoxyestradiol: new developments</article-title>. <source>Drug Resist Updat</source>. <year>2003</year>;<volume>6</volume>(<issue>6</issue>):<fpage>355</fpage>–<lpage>361</lpage>.</citation>
</ref>
<ref id="bibr84-1933719112446080">
<label>84</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Role of JNK activation in apoptosis: a double-edged sword</article-title>. <source>Cell Res</source>. <year>2005</year>;<volume>15</volume>(<issue>1</issue>):<fpage>36</fpage>–<lpage>42</lpage>.</citation>
</ref>
<ref id="bibr85-1933719112446080">
<label>85</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chauhan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hideshima</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group> <article-title>JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells</article-title>. <source>J Biol Chem</source>. <year>2003</year>;<volume>278</volume>(<issue>20</issue>):<fpage>17593</fpage>–<lpage>17596</lpage>.</citation>
</ref>
<ref id="bibr86-1933719112446080">
<label>86</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ting</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>YM</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>CK</given-names>
</name>
</person-group>
<etal/> <article-title>2-Methoxyestradiol induces endoreduplication through the induction of mitochondrial oxidative stress and the activation of MAPK signaling pathways</article-title>. <source>Biochem Pharmacol</source>. <year>2010</year>;<volume>79</volume>(<issue>6</issue>):<fpage>825</fpage>–<lpage>841</lpage>.</citation>
</ref>
<ref id="bibr87-1933719112446080">
<label>87</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fukui</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>BT</given-names>
</name>
</person-group>. <article-title>Mechanism of 2-methoxyestradiol-induced apoptosis and growth arrest in human breast cancer cells</article-title>. <source>Mol Carcinog</source>. <year>2009</year>;<volume>48</volume>(<issue>1</issue>):<fpage>66</fpage>–<lpage>78</lpage>.</citation>
</ref>
<ref id="bibr88-1933719112446080">
<label>88</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Rahmani</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dent</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Grant</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>2-Methoxyestradiol-induced apoptosis in human leukemia cells proceeds through a reactive oxygen species and Akt-dependent process</article-title>. <source>Oncogene</source>. <year>2005</year>;<volume>24</volume>(<issue>23</issue>):<fpage>3797</fpage>–<lpage>3809</lpage>.</citation>
</ref>
<ref id="bibr89-1933719112446080">
<label>89</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Djavaheri-Mergny</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wietzerbin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Besancon</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>2-Methoxyestradiol induces apoptosis in Ewing</article-title> <article-title>sarcoma cells through mitochondrial hydrogen peroxide production</article-title>. <source>Oncogene</source>. <year>2003</year>;<volume>22</volume>(<issue>17</issue>):<fpage>2558</fpage>–<lpage>2567</lpage>.</citation>
</ref>
<ref id="bibr90-1933719112446080">
<label>90</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>She</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>KY</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>XQ</given-names>
</name>
</person-group>. <article-title>Requirement of reactive oxygen species generation in apoptosis of leukemia cells induced by 2-methoxyestradiol</article-title>. <source>Acta Pharmacol Sin</source>. <year>2007</year>;<volume>28</volume>(<issue>7</issue>):<fpage>1037</fpage>–<lpage>1044</lpage>.</citation>
</ref>
<ref id="bibr91-1933719112446080">
<label>91</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sattler</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Quinnan</surname>
<given-names>LR</given-names>
</name>
<name>
<surname>Pride</surname>
<given-names>YB</given-names>
</name>
</person-group>
<etal/> <article-title>2-Methoxyestradiol alters cell motility, migration, and adhesion</article-title>. <source>Blood</source>. <year>2003</year>;<volume>102</volume>(<issue>1</issue>):<fpage>289</fpage>–<lpage>296</lpage>.</citation>
</ref>
<ref id="bibr92-1933719112446080">
<label>92</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pani</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Colavitti</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bedogni</surname>
<given-names>B</given-names>
</name>
</person-group>
<etal/> <article-title>Mitochondrial superoxide dismutase: a promising target for new anticancer therapies</article-title>. <source>Curr Med Chem</source>. <year>2004</year>;<volume>11</volume>(<issue>10</issue>):<fpage>1299</fpage>–<lpage>1308</lpage>.</citation>
</ref>
<ref id="bibr93-1933719112446080">
<label>93</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mabjeesh</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Escuin</surname>
<given-names>D</given-names>
</name>
</person-group>, <article-title>LaVallee TM, et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF</article-title>. <source>Cancer Cell</source>. <year>2003</year>;<volume>3</volume>(<issue>4</issue>):<fpage>363</fpage>–<lpage>375</lpage>.</citation>
</ref>
<ref id="bibr94-1933719112446080">
<label>94</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Semenza</surname>
<given-names>GL</given-names>
</name>
</person-group>. <article-title>Oxygen sensing, homeostasis, and disease</article-title>. <source>N Engl J Med</source>. <year>2011</year>;<volume>365</volume>(<issue>6</issue>):<fpage>537</fpage>–<lpage>547</lpage>.</citation>
</ref>
<ref id="bibr95-1933719112446080">
<label>95</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chua</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Chua</surname>
<given-names>YL</given-names>
</name>
<name>
<surname>Hagen</surname>
<given-names>T</given-names>
</name>
</person-group>. <article-title>Structure activity analysis of 2-methoxyestradiol analogues reveals targeting of microtubules as the major mechanism of antiproliferative and proapoptotic activity</article-title>. <source>Mol Cancer Ther</source>. <year>2010</year>;<volume>9</volume>(<issue>1</issue>):<fpage>224</fpage>–<lpage>235</lpage>.</citation>
</ref>
<ref id="bibr96-1933719112446080">
<label>96</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dang</surname>
<given-names>DT</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Gardner</surname>
<given-names>LB</given-names>
</name>
</person-group>
<etal/> <article-title>Hypoxia-inducible factor-1alpha promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts</article-title>. <source>Cancer Res</source>. <year>2006</year>;<volume>66</volume>(<issue>3</issue>):<fpage>1684</fpage>–<lpage>1936</lpage>.</citation>
</ref>
<ref id="bibr97-1933719112446080">
<label>97</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carmeliet</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Dor</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Herbert</surname>
<given-names>JM</given-names>
</name>
</person-group>
<etal/> <article-title>Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis</article-title>. <source>Nature</source>. <year>1998</year>;<volume>394</volume>(<issue>6692</issue>):<fpage>485</fpage>–<lpage>490</lpage>.</citation>
</ref>
<ref id="bibr98-1933719112446080">
<label>98</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ryan</surname>
<given-names>HE</given-names>
</name>
<name>
<surname>Poloni</surname>
<given-names>M</given-names>
</name>
<name>
<surname>McNulty</surname>
<given-names>W</given-names>
</name>
</person-group>
<etal/> <article-title>Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth</article-title>. <source>Cancer Res</source>. <year>2000</year>;<volume>60</volume>(<issue>15</issue>):<fpage>4010</fpage>–<lpage>4015</lpage>.</citation>
</ref>
<ref id="bibr99-1933719112446080">
<label>99</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fotsis</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Pepper</surname>
<given-names>MS</given-names>
</name>
</person-group>
<etal/> <article-title>The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth</article-title>. <source>Nature</source>. <year>1994</year>;<volume>368</volume>(<issue>6468</issue>):<fpage>237</fpage>–<lpage>239</lpage>.</citation>
</ref>
<ref id="bibr100-1933719112446080">
<label>100</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klauber</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Parangi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Flynn</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hamel</surname>
<given-names>E</given-names>
</name>
<name>
<surname>D'Amato</surname>
<given-names>RJ</given-names>
</name>
</person-group>. <article-title>Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol</article-title>. <source>Cancer Res</source>. <year>1997</year>;<volume>57</volume>(<issue>1</issue>):<fpage>81</fpage>–<lpage>86</lpage>.</citation>
</ref>
<ref id="bibr101-1933719112446080">
<label>101</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lakhani</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Sarkar</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Venitz</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Figg</surname>
<given-names>WD</given-names>
</name>
</person-group>. <article-title>2-Methoxyestradiol, a promising anticancer agent</article-title>. <source>Pharmacotherapy</source>. <year>2003</year>;<volume>23</volume>(<issue>2</issue>):<fpage>165</fpage>–<lpage>172</lpage>.</citation>
</ref>
<ref id="bibr102-1933719112446080">
<label>102</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>LaVallee</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Zhan</surname>
<given-names>XH</given-names>
</name>
<name>
<surname>Herbstritt</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Kough</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>SJ</given-names>
</name>
</person-group>, <article-title>Pribluda VS. 2-Methoxyestradiol inhibits proliferation and induces apoptosis independently of estrogen receptors alpha and beta</article-title>. <source>Cancer Res</source>. <year>2002</year>;<volume>62</volume>(<issue>13</issue>):<fpage>3691</fpage>–<lpage>3697</lpage>.</citation>
</ref>
<ref id="bibr103-1933719112446080">
<label>103</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lippert</surname>
<given-names>TH</given-names>
</name>
<name>
<surname>Adlercreutz</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Berger</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Seeger</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Elger</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Mueck</surname>
<given-names>AO</given-names>
</name>
</person-group>. <article-title>Effect of 2-methoxyestradiol on the growth of methyl-nitroso-urea (MNU)-induced rat mammary carcinoma</article-title>. <source>J Steroid Biochem Mol Biol</source>. <year>2003</year>;<volume>84</volume>(<issue>1</issue>):<fpage>51</fpage>–<lpage>56</lpage>.</citation>
</ref>
<ref id="bibr104-1933719112446080">
<label>104</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>BT</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>GZ</given-names>
</name>
<name>
<surname>Shim</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Wen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>XR</given-names>
</name>
</person-group>. <article-title>Quantitative structure-activity relationship of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: Insights into the structural determinants favoring a differential subtype binding</article-title>. <source>Endocrinology</source>. <year>2006</year>;<volume>147</volume>(<issue>9</issue>):<fpage>4132</fpage>–<lpage>4150</lpage>.</citation>
</ref>
<ref id="bibr105-1933719112446080">
<label>105</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sutherland</surname>
<given-names>TE</given-names>
</name>
<name>
<surname>Schuliga</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>T</given-names>
</name>
</person-group>
<etal/> <article-title>2-Methoxyestradiol is an estrogen receptor agonist that supports tumor growth in murine xenograft models of breast cancer</article-title>. <source>Clin Cancer Res</source>. <year>2005</year>;<volume>11</volume>(<issue>5</issue>):<fpage>1722</fpage>–<lpage>1732</lpage>.</citation>
</ref>
<ref id="bibr106-1933719112446080">
<label>106</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCormick</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Pribluda</surname>
<given-names>V</given-names>
</name>
</person-group>
<etal/> <article-title>Preclinical development of 2-methoxyestradiol (2ME2. NSC-659853)</article-title>. <source>Proc Am Assoc Cancer Res</source>. <year>2000</year>;<volume>41</volume>:<fpage>328</fpage>.</citation>
</ref>
<ref id="bibr107-1933719112446080">
<label>107</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lucidi</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Witz</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Chrisco</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Binkley</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Shain</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Schenken</surname>
<given-names>RS</given-names>
</name>
</person-group>. <article-title>A novel in vitro model of the early endometriotic lesion demonstrates that attachment of endometrial cells to mesothelial cells is dependent on the source of endometrial cells</article-title>. <source>Fertil Steril</source>. <year>2005</year>;<volume>84</volume>(<issue>1</issue>):<fpage>16</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr108-1933719112446080">
<label>108</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Laschke</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Menger</surname>
<given-names>MD</given-names>
</name>
</person-group>. <article-title>In vitro and in vivo approaches to study angiogenesis in the pathophysiology and therapy of endometriosis</article-title>. <source>Hum Reprod Update</source>. <year>2007</year>;<volume>13</volume>(<issue>4</issue>):<fpage>331</fpage>–<lpage>342</lpage>.</citation>
</ref>
<ref id="bibr109-1933719112446080">
<label>109</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herington</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Bruner-Tran</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Lucas</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Osteen</surname>
<given-names>KG</given-names>
</name>
</person-group>. <article-title>Immune interactions in endometriosis</article-title>. <source>Expert Rev Clin Immunol</source>. <year>2011</year>;<volume>7</volume>(<issue>5</issue>):<fpage>611</fpage>–<lpage>626</lpage>.</citation>
</ref>
<ref id="bibr110-1933719112446080">
<label>110</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>D'Hooghe</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Debrock</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hill</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Meuleman</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Endometriosis and subfertility: is the relationship resolved?</article-title> <source>Semin Reprod Med</source>. <year>2003</year>;<volume>21</volume>(<issue>2</issue>):<fpage>243</fpage>–<lpage>254</lpage>.</citation>
</ref>
<ref id="bibr111-1933719112446080">
<label>111</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keenan</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>TT</given-names>
</name>
<name>
<surname>Chadwell</surname>
<given-names>NL</given-names>
</name>
<name>
<surname>Torry</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Caudle</surname>
<given-names>MR</given-names>
</name>
</person-group>. <article-title>Interferon-gamma (IFN-gamma) and interleukin-6 (IL-6) in peritoneal fluid and macrophage-conditioned media of women with endometriosis</article-title>. <source>Am J Reprod Immunol</source>. <year>1994</year>;<volume>32</volume>(<issue>3</issue>):<fpage>180</fpage>–<lpage>183</lpage>.</citation>
</ref>
<ref id="bibr112-1933719112446080">
<label>112</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rana</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Braun</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>House</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gebel</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Rotman</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Dmowski</surname>
<given-names>WP</given-names>
</name>
</person-group>. <article-title>Basal and stimulated secretion of cytokines by peritoneal macrophages in women with endometriosis</article-title>. <source>Fertil Steril</source>. <year>1996</year>;<volume>65</volume>(<issue>5</issue>):<fpage>925</fpage>–<lpage>930</lpage>.</citation>
</ref>
<ref id="bibr113-1933719112446080">
<label>113</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Halme</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wing</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Accentuated cyclic activation of peritoneal macrophages in patients with endometriosis</article-title>. <source>Am J Obstet Gynecol</source>. <year>1984</year>;<volume>148</volume>(<issue>1</issue>):<fpage>85</fpage>–<lpage>90</lpage>.</citation>
</ref>
<ref id="bibr114-1933719112446080">
<label>114</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bacci</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Capobianco</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Monno</surname>
<given-names>A</given-names>
</name>
</person-group>
<etal/> <article-title>Macrophages are alternatively activated in patients with endometriosis and required for growth and vascularization of lesions in a mouse model of disease</article-title>. <source>Am J Pathol</source>. <year>2009</year>;<volume>175</volume>(<issue>2</issue>):<fpage>547</fpage>–<lpage>556</lpage>.</citation>
</ref>
<ref id="bibr115-1933719112446080">
<label>115</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Plum</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Strawn</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>EG</given-names>
</name>
<name>
<surname>Sidor</surname>
<given-names>CF</given-names>
</name>
<name>
<surname>Fogler</surname>
<given-names>WE</given-names>
</name>
</person-group>. <article-title>Disease modifying and antiangiogenic activity of 2-methoxyestradiol in a murine model of rheumatoid arthritis</article-title>. <source>BMC Musculoskelet Disord</source>. <year>2009</year>;<volume>10</volume>:<fpage>46</fpage>.</citation>
</ref>
<ref id="bibr116-1933719112446080">
<label>116</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tofovic</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Petrusevska</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>2-Methoxyestradiol attenuates bleomycin-induced pulmonary hypertension and fibrosis in estrogen-deficient rats</article-title>. <source>Vascul Pharmacol</source>. <year>2009</year>;<volume>51</volume>(<issue>2-3</issue>):<fpage>190</fpage>–<lpage>197</lpage>.</citation>
</ref>
<ref id="bibr117-1933719112446080">
<label>117</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shand</surname>
<given-names>FH</given-names>
</name>
<name>
<surname>Langenbach</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Keenan</surname>
<given-names>CR</given-names>
</name>
</person-group>
<etal/> <article-title>In vitro and in vivo evidence for anti-inflammatory properties of 2-methoxyestradiol</article-title>. <source>J Pharmacol Exp Ther</source>. <year>2011</year>;<volume>336</volume>(<issue>3</issue>):<fpage>962</fpage>–<lpage>972</lpage>.</citation>
</ref>
<ref id="bibr118-1933719112446080">
<label>118</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Issekutz</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Sapru</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Modulation of adjuvant arthritis in the rat by 2-methoxyestradiol: an effect independent of an anti-angiogenic action</article-title>. <source>Int Immunopharmacol</source>. <year>2008</year>;<volume>8</volume>(<issue>5</issue>):<fpage>708</fpage>–<lpage>716</lpage>.</citation>
</ref>
<ref id="bibr119-1933719112446080">
<label>119</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bonacasa</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Sanchez</surname>
<given-names>ML</given-names>
</name>
</person-group>, <article-title>Rodriguez F, et al. 2-Methoxyestradiol attenuates hypertension and coronary vascular remodeling in spontaneously hypertensive rats</article-title>. <source>Maturitas</source>. <year>2008</year>;<volume>61</volume>(<issue>4</issue>):<fpage>310</fpage>–<lpage>316</lpage>.</citation>
</ref>
<ref id="bibr120-1933719112446080">
<label>120</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dubey</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Gillespie</surname>
<given-names>DG</given-names>
</name>
<name>
<surname>Keller</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Imthurn</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zacharia</surname>
<given-names>LC</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>EK</given-names>
</name>
</person-group>. <article-title>Role of methoxyestradiols in the growth inhibitory effects of estradiol on human glomerular mesangial cells</article-title>. <source>Hypertension</source>. <year>2002</year>;<volume>39</volume>(<issue>2 Pt 2</issue>):<fpage>418</fpage>–<lpage>424</lpage>.</citation>
</ref>
<ref id="bibr121-1933719112446080">
<label>121</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanasaki</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Palmsten</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sugimoto</surname>
<given-names>H</given-names>
</name>
</person-group>
<etal/> <article-title>Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with pre-eclampsia</article-title>. <source>Nature</source>. <year>2008</year>;<volume>453</volume>(<issue>7198</issue>):<fpage>1117</fpage>–<lpage>1121</lpage>.</citation>
</ref>
<ref id="bibr122-1933719112446080">
<label>122</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dragun</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Haase-Fielitz</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Low catechol-O-methyltransferase and 2-methoxyestradiol in preeclampsia: more than a unifying hypothesis</article-title>. <source>Nephrol Dial Transplant</source>. <year>2009</year>;<volume>24</volume>(<issue>1</issue>):<fpage>31</fpage>–<lpage>33</lpage>.</citation>
</ref>
<ref id="bibr123-1933719112446080">
<label>123</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stone</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Sood</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Coleman</surname>
<given-names>RL</given-names>
</name>
</person-group>. <article-title>Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer</article-title>. <source>Lancet Oncol</source>. <year>2010</year>;<volume>11</volume>(<issue>5</issue>):<fpage>465</fpage>–<lpage>475</lpage>.</citation>
</ref>
<ref id="bibr124-1933719112446080">
<label>124</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verenich</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gerk</surname>
<given-names>PM</given-names>
</name>
</person-group>. <article-title>Therapeutic promises of 2-methoxyestradiol and its drug disposition challenges</article-title>. <source>Mol Pharm</source>. <year>2010</year>;<volume>7</volume>(<issue>6</issue>):<fpage>2030</fpage>–<lpage>2039</lpage>.</citation>
</ref>
<ref id="bibr125-1933719112446080">
<label>125</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dahut</surname>
<given-names>WL</given-names>
</name>
<name>
<surname>Lakhani</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Gulley</surname>
<given-names>JL</given-names>
</name>
</person-group>
<etal/> <article-title>Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors</article-title>. <source>Cancer Biol Ther</source>. <year>2006</year>;<volume>5</volume>(<issue>1</issue>):<fpage>22</fpage>–<lpage>27</lpage>.</citation>
</ref>
<ref id="bibr126-1933719112446080">
<label>126</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tevaarwerk</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Holen</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Alberti</surname>
<given-names>DB</given-names>
</name>
</person-group>
<etal/> <article-title>Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies</article-title>. <source>Clin Cancer Res</source>. <year>2009</year>;<volume>15</volume>(<issue>4</issue>):<fpage>1460</fpage>–<lpage>1465</lpage>.</citation>
</ref>
<ref id="bibr127-1933719112446080">
<label>127</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Molema</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Tumor vasculature directed drug targeting: applying new technologies and knowledge to the development of clinically relevant therapies</article-title>. <source>Pharm Res</source>. <year>2002</year>;<volume>19</volume>(<issue>9</issue>):<fpage>1251</fpage>–<lpage>1258</lpage>.</citation>
</ref>
<ref id="bibr128-1933719112446080">
<label>128</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yeh</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Chou</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>CC</given-names>
</name>
</person-group>
<etal/> <article-title>Anticancer agent 2-methoxyestradiol improves survival in septic mice by reducing the production of cytokines and nitric oxide</article-title>. <source>Shock</source>. <year>2011</year>;<volume>36</volume>(<issue>5</issue>):<fpage>510</fpage>–<lpage>516</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>